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ABSTRACT 
THE BETA- 2 ADRENERGIC RECEPTOR POL YMORPHISMS AND RISK OF 
BREAST CANCER AMONG HISPANIC AND NON-HISPANIC WHITE WOMEN 
FROM THE 4-CORNERS BREAST CANCER STUDY- A POPULATION-BASED 
CASE-CONTROL EXAMINATION 
A vonne E. Connor 
July21,2011 
Polymorphisms in the adrenergic receptor beta-2 (ADRB2) gene have been 
studied in relation to risk of Type 2 diabetes and obesity, but few studies have 
investigated associations with breast cancer. The purpose of this research was to evaluate 
the primary hypothesis that ADRB2 variants (rs1042713-Arg16Gly and rs1042714-
Gln27Glu) are associated with breast cancer risk in non-Hispanic white (NHW) and 
Hispanic (H) women using data from a population-based case-control study conducted in 
the southwestern United States: 'The 4-Corners Breast Cancer Study'. A total of 1,244 
NHW and 606 H cases with incident primary breast cancer were ascertained and 1,330 
NHW and 728 H population-based controls were selected. Information on lifestyle and 
physical activity, diet, demographics, and reproductive background was collected through 
an in-person questionnaire, and blood samples were taken for genetic analyses from 
consenting participants. ADRB2 genotypes for rs 1042713 and rs 1042714 were 
determined using PCR. Each genotype as well as their haplotypes was evaluated in 
multi variable logistic regression models to estimate the associations with breast cancer 
v 
risk, while adjusting for potential confounders, including study center, history of 
diabetes, body mass index, genetic admixture, and menopausal status. 
ADRB2 genotype frequencies were significantly different between NHW and H 
women. Individually, the ADRB2 polymorphisms were not associated with breast cancer 
in either ethnic group. However, having 2 copies compared to one or zero copies of the 
ADRB2 G-G haplotype was associated significantly with increased risk of breast cancer 
among NHW women [odds ratio (OR), 1.95; 95% confidence interval (95% CI), 1.26-
3.01] but reduced risk among Hispanic women [OR, 0.74; 95% CI, 0.50-1.09], (p-for 
interaction= 0.004). Risk was significantly decreased in Hispanic women with a history 
of Type 2 diabetes and 2 copies of the G-G haplotype [OR, 0.33; 95% CI, 0.12-0.92] 
while the association was increased, but not statistically significant among NHW women, 
[OR, 4.91; 95% CI, 0.52-46.60], (p-for interaction = 0.025). While the interaction 
between obesity (body mass index (BMI) ~ 30 kg/m2) and the G-G haplotype was not 
significant (p= 0.200), the association in NHW obese women with 2 copies of the G-G 
haplotype was similarly increased [OR, 3.01; 95% CI, 1.22-7.44], but decreased in 
Hispanics [OR, 0.42; 95% CI, 0.20-0.56]. These data suggest that ethnicity modifies the 
association between the ADRB2 G-G haplotype and breast cancer risk and history of 
Type 2 diabetes and obesity enhances the divergence of risk between Hispanic and NHW 
women. 
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INTRODUCTION 
Specific Aims, Hypotheses, and Background 
Specific Aims and Hypothesis 
Polymorphisms in the adrenergic receptor beta-2 (ADRB2) gene have been 
studied in relation to risk of Type 2 diabetes and obesity, but few studies have 
investigated associations with breast cancer. It has been postulated that genetic traits 
related to obesity and obesity-related diseases could possibly influence the risk of breast 
cancer, given the known relationship between obesity and postmenopausal breast cancer. 
The purpose of this study is to evaluate the primary hypotheses that the following 
ADRB2 polymorphisms (rsl042713 (Arg16Gly) and rsl042714 (Gln27Glu) are 
associated with breast cancer risk in non-Hispanic white and Hispanic women using data 
from a population-based case-control study, 'The 4-Corners Breast Cancer Study'. The 
specific aims to conduct this proposed dissertation study and primary hypotheses are 
detailed below: 
(1) To assay the following SNPs in the ADRB2 gene (rsl042714 (Gln27Glu), 
rsl042713 (Arg16Gly)) using stored DNA from the 4-Corners Breast Cancer 
Study. 
(2) To determine the statistical associations of individual SNPs (rs1042714 
(Gln27Glu), rsl042713 (Arg16Gly)) and their haplotypes with breast cancer risk. 
(3) To determine the statistical interactions of the SNPs with theoretically defined 
effect modifiers including family history, ethnicity, obesity, menopausal status, 
estrogen receptor status, NSAID use, aspirin use, and functional SNPs in the 
following insulin/obesity related genes: IRS1, IRS2, IGF1, ADRB3, and IL6. 
(4) To determine the statistical associations of individual SNPs (rsl042714 
(Gln27Glu), rs1042713 (Arg16Gly» and their haplotypes with obesity risk 
measured by body mass index and risk of Type 2 diabetes. 
(5) To determine the statistical associations of individual SNPs (rs1042714 
(Gln27Glu), rs1042713 (Arg16Gly» and their haplotypes with risk of breast 
cancer categorized by estrogen receptor status. 
HIA: The risk of breast cancer for women who have the ADBR2 (rs1042714 (Gln27Glu), 
rs1 042713 (Arg16Gly» variant genotypes will be higher than for those who do not have 
the minor homozygous genotype, after adjustment for other relevant confounders. 
H2A: The risk of breast cancer for women who have the ADRB2 haplotypes for the 
variants rs1042714 (Gln27Glu) and rs1042713 (Arg16Gly) will be higher than for those 
who do not have the minor disease causing haplotypes, after adjustment for other relevant 
confounders. 
HIB : The risk of breast cancer for women with the ADRB2 variant(s) will be modified by 
family history, ethnicity (non-Hispanic white vs. Hispanic ethnicity), markers for obesity 
(BMI) menopausal status, aspirin use, NSAID use, estrogen receptor status (ER+/ER-), 
IRS-1 (rsI801278) and IRS-2 (rsI805097) variants, and other previously measured 
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insulin/obesity related genes (IGFI, ADRB3) after controlling for other important 
covariates. 
H2B : The proposed relationship between breast cancer for women with the ADRB2 
variants and markers for obesity (BMI, waist circumference, waist/hip ratio) will 
demonstrate significant results for effect mediation. 
H3S: The risk for obesity and Type 2 diabetes for women who have the rsI0427I4 
(Gln27Glu) and rsI0427I3 (ArgI6Gly) variant alleles and genotypes will be higher than 
for those who do not have the minor homozygous genotype, after adjustment for other 
relevant confounders. 
H4S : The risk for estrogen receptor negative tumors for women who have the rsI0427I4 
(Gln27Glu) and rs1042713 (ArgI6Gly) variant genotypes will be higher than for those 
who do not have the minor homozygous genotype, after adjustment for other relevant 
confounders. 
Important covariates to consider for the study analyses are: age, ethnicity, education, 
aspirin usage, NSAID usage, height, BMI at referent year, WHR categorized, waist 
circumference (centimeters), menstruation start age, menopausal status, age at first birth, 
parity, smoking status, physical activity, caloric intake, family history of breast cancer, 
diabetes history, IRS-I, IRS-2, IGFI, ADRB3, and IL6 variants (all of which are 
previously measured insulin/obesity related genes). 
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Background 
Adrenergic Receptor Beta 2 (ADRB2) 
The beta-2-adrenergic receptor is a member of the G-protein-coupled adrenergic 
receptor family. It binds and is activated by catecholamines, more specifically 
epinephrine. The gene that codes for the beta-2-adrenergic receptor, the ADRB2 gene, is 
located on chromosome 5q31-q32 and consists of a single exon of 20 15 nucleotides, 
encoding 413 amino acid proteins. ADRB2 has been found to regulate several systems 
through agonist-mediated vascular response, including the cardiac, pulmonary, vascular, 
endocrine, and central nervous systems [1]. 
There are over 80 polymorphisms for ADRB2, of which 45 SNPs have been 
identified. There are two non-synonymous SNPs that are more common which code for 
amino acid changes at positions 16 [arginine to glycine-Argl6Gly (rsl042713)] and 27 
[glutamic acid to glutamine-Glu27Gln (rsl042714)] [1]. Previous literature has referred 
to the rsl042714 polymorphism as Glu27Gln, however throughout this dissertation study 
report, the rsl042714 is referred to as Gln27Glu [2]. The nucleotide changes for 
rsl042713 and rsl042714 are Exl+265G>A and Exl+298G>C, respectively. These 
common ADRB2 SNPs have been found to be associated with risk of Type 2 diabetes [3-
5] and are suspected to playa role with risk of obesity in certain populations [6-8]; 
however, recent literature has documented mixed findings. lalba et al. found the Glu27 
allele to be associated with obesity in Asians, Pacific Islanders, and American Indians, 
but not among Europeans. They also concluded there was no association found between 
the Arg16 allele and obesity [6]. It is known that the beta adrenergic receptors function in 
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the adipose tissue by stimulating lipolysis, which in part could affect the regulation of 
energy expenditure and lipid mobilization within human fat cells [9]. 
Biological studies have indicated a carcinogenic role with the beta-2 adrenergic 
receptors in breast cancer cell lines through the over-expression of the arachidonic acid-
metabolizing enzymes cyclooxygenase-2 and lypoxygenases [10]. Arachidonic acid (AA) 
metabolism can produce mutagens that can damage DNA and cause mutations. It has also 
been found that modulation of pathways for the AA metabolizing enzymes 
cyclooxygenase-2 and lypoxygenases can result in suppression of tumor growth [11]. 
Biological evidence of this mechanism for carcinogenesis has been found for 
adenocarcinomas of the lungs, pancreas and colon, all of which have demonstrated over 
expression of the arachidonic-metabolizing enzymes, presumably under beta-adrenergic 
control [10, 12]. Plummer et al. hypothesized that the beta-adrenergic regulation of the 
arachidonic acid-mediated signaling occurs in breast adenocarcinomas by way of G-
protein coupled inwardly rectifying potassium channels (GIRKI). The expression of 
mRNA encoded with GIRKI has been found in roughly 40% of primary human breast 
cancer tissue samples [12]. 
Vandewalle et al. previously confirmed that the beta adrenergic compounds 
stimulated cAMP production in breast cancer cells. The production of cAMP has been 
implicated with tumor growth mechanisms and in lactose production [13]. Researchers 
have also speculated that specific beta-adrenergic receptors coupled with G protein could 
playa role with circulating catecholamines which could function in the growth and 
differentiation of the mammary glands [14]. The pathophysiological significance of the 
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beta-adrenergic receptors remains uncertain and more biological research is needed to 
explain their physiological role with the development of breast cancer. 
Few epidemiological studies have examined the possible relationship of ADRB2 
with breast cancer risk, based upon the relationship between obesity and postmenopausal 
breast cancer [15 -16]. The assumption proposed by these investigators is that an indirect 
relationship may exist between genetic traits linked to obesity and risk of postmenopausal 
breast cancer. Huang et al. utilized a small sample of 200 breast cancer cases and 182 
controls from Japan to investigate this association, and oddly found a non-statistically 
significant inverse association between rsl042714 Glu vs. GIn/Gin and breast cancer risk; 
OR=0.67, 95%CI: (0.38-1.18) [15]. In a nested case-control study among 
postmenopausal women from the American Cancer Society Cancer Prevention Study II 
Nutrition Cohort, Feigelson et al. [16] also investigated the relationship between ADRB2 
in addition to other obesity related genes and breast cancer risk among 648 cases and 659 
controls. The majority of women who participated were non-Hispanic white, while 
African American women only made up 12% of the study sample. For this particular 
study, tagging SNPs for ADRB2 were utilized to test for the associations. From the 
tagging SNPs identified (rs87741, rs2400707, rs10472718, and rs17108817), no 
statistically significant associations were found for breast cancer risk after adjusting for 
ethnicity, birth date, blood draw date, adult weight change, breast cysts, family history of 
breast cancer, and postmenopausal hormone use [16]. 
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Adrenergic Receptor Beta 3 (ADRB3) 
Located on chromosome 8p, the adrenergic receptor beta 3 (ADRB3) has also 
been found to function in lipolysis and thermogenesis. Although the ADRB3 gene codes 
for 396 amino acids, little is known about other functional roles of this gene. Human fat 
cells are the only human cells available for ADRB3 functional studies [17-18]. The 
ADRB3 polymorphism Trp64! Arg has been implicated with the development of obesity 
and Type 2 diabetes, but conflicting results have been found. According to Arner et aI, at 
least 15 studies have found no association between the Try64! Arg polymorphism and 
obesity [18]. In a meta-analysis by Kurokawa et aI., the ADRB3 polymorphism was 
associated with BMI among east Asians, but not for Europeans [19]. In a study of African 
American breast cancer cases from the Health, Eating, Activity and Lifestyle Study, 
researchers found an increased risk of obesity among women who were homozygous for 
the ADRB3 wild-type allele (OR=2.1, 95% CI: 1.1-4.2) [20]. In a population of Danish 
subjects, the variant Arg64 was not found to be associated with risk of obesity but was 
found to be positively associated with Type 2 diabetes and increased insulin resistance 
[21]. Dunajska and colleagues did not find an association between the Arg64 variant 
with risk of developing metabolic syndrome among postmenopausal women [22], but 
interestingly, a positive association was found among obese males [23]. 
The association of the ADRB3 polymorphism Trp64!Arg with risk of breast 
cancer has also been investigated through epidemiological studies. Huang et al. also 
investigated the association of the Arg64 variant with breast cancer risk, but found an 
inverse association among their small case-control study (OR= 0.85; 95% CI: 0.55-1.31) 
[15]. As previously mentioned, Feigelson et al. also examined the ADRB3 
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polymorphism in relation to breast cancer risk, and did not find an association, as with 
the selected ADRB2 variants [16]. The ADRB3 Try64/Arg polymorphism has been 
genotyped and analyzed prior to this dissertation as part of the 4-Corners Breast Cancer 
Study. Due to similarities between the physiological functions of ADRB2 and ADRB3 
genes, interaction effects between these polymorphisms and risk of breast cancer are of 
interest for this dissertation study. 
Insulin Receptor Substrate I and 2 (IRS-I and IRS2) 
Insulin receptor substrates (IRSs) are intracellular proteins that function as 
signaling adaptors in the metabolic and mitogenic processes associated with hormone, 
cytokine, and growth factor signaling [24]. Within the past few years, more evidence has 
been found that implicates a link between IRSs activity and human cancer. In a study of 
breast cancer patients, it was reported that high IRS-l levels were associated with poor 
outcomes [25]. In a later molecular study, mice that overexpressed human IRS-lor IRS-2 
in mammary tissue demonstrated advanced mammary hyperplasia, tumorigenesis, and 
metastasis; phenotypes were also associated with activation of ~-catenin [24]. These IRS 
proteins also bonded with ~-catenin in vitro and in vivo [24]. Interestingly in recent 
molecular cancer research, Bommer et al [26] demonstrated that the IRS-l gene 
expression can be directly activated by ~-catenin through the ~-catenin/TCF complex that 
binds with elements downstream of the IRS-l transcriptional start site. This study also 
found that IRS 1 is highly expressed in cancers that demonstrate ~-catenin stabilization 
[26]. 
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In epidemiological research, the role of the IRS genes have been investigated with 
their relationship with breast cancer based upon their connection with cancer and other 
conditions that are considered important contributing factors for cancer risk [27]. As 
with specific variants of the ADRB2 gene, the IRSI polymorphism rsI801278, also 
known as G972R has been associated with insulin resistance and Type 2 diabetes, and 
the R allele has been found to increase the risk of colon cancer [28]. The IRS2 gene has 
also been found to be associated with obesity [29-30]. Using data from the 4-Corners 
Breast Cancer Study, Slattery et al. [27] investigated the relationship between IRS 1 
(G972R) and IRS2 (G 1 057D) and breast cancer risk, among other genetic 
polymorphisms. Postmenopausal women who had the R allele of the G972R IRS 1 
polymorphism (rs 180 1278) and were not recently exposed to hormones were found to 
have an increased risk of breast cancer (OR=2.70, 95%CI: 1.13-6.46) after controlling for 
age, center, parity, energy intake, physical activity, and genetic admixture, [27]. An 
important factor to consider from this study is that these associations differed by 
ethnicity, which illuminates the importance of considering different metabolic pathways 
that may influence breast cancer risk which may vary between ethnic groups, possibly 
due to the genetic variation between ethnicities. 
In the recent population-based breast cancer study conducted by Feigelson et al. 
[16], the associations between breast cancer and several candidate obesity genes, 
including IRS 1 and IRS2 variants, were examined. This primarily non-Hispanic white 
sample considered the following covariates as potential confounders: BMI, adult weight 
change, postmenopausal hormone use, family history of breast cancer, and history of 
breast cysts. Effect modification was also tested for between genotypes and BMI, 
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postmenopausal hormone use, family history of breast cancer, and history of breast cysts. 
Results did not demonstrate an association between IRS 1 SNPs and breast cancer; 
however, three of the SNPS for IRS2 did show a significant association with breast 
cancer risk (rs4773082, P=0.007, rs2289046, P=0.016, rs754204, P=0.03) [16]. Although 
these findings with the three IRS2 variants were significant, the authors noted that they 
were not able to genotype the IRS2 variant rs 1805097 due to assay failure. 
The other genes and their functional SNPs proposed for interaction effects that 
have been previously genotyped in the parent study were selected for this proposed 
dissertation study based on their potential role in a pathway linking energy balance and 
obesity to breast cancer through estrogen, insulin, and insulin-like growth factors [27,31-
33]. 
Obesity, Ethnicity, and Breast Cancer 
The link between the ADRB2 gene and obesity is unclear; however, examining 
interaction effects between obesity predictors, the ADRB2 variants, and breast cancer 
risk or investigating by subgroup analyses seems logical given that obesity has been 
found to be associated with breast cancer. It is important to consider that the association 
with body size and breast cancer differs for premenopausal and postmenopausal breast 
cancers. For postmenopausal breast cancer, larger body size is associated with an 
increased risk for disease; this finding is believed to be attributed to the conversion of 
precursor substrates to estrogen in adipose tissue [34]. Contrastingly, for premenopausal 
women, an inverse association has been found between risk for breast cancer and 
increased adiposity [34]. Premenopausal who are overweight or obese may have a 
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reduced risk of breast cancer due to increased frequency of anovulatory cycles [35] or 
due to increased parity, which tends to be associated with increased weight [36]. 
Various anthropometric measurements are used to describe adiposity including 
body mass index (BMI m/kg\ waist circumference, and waist-hip-ratio (WHR). The 
relationship between these measurements and breast cancer risk has been widely 
researched. Results have been mixed as to which is the most accurate anthropometric 
predictor for breast cancer risk. Meta-analyses have shown for every unit increase in 
BMI, there is approximately a 3% increase in risk of postmenopausal breast cancer [37]. 
In the EPIC cohort study, waist circumference was associated with breast cancer risk with 
a relative risk of 1.12, 95%CI: (1.02-1.24) per 10 cm increase in waist circumference 
measure, and for hip circumference, a relative risk of 1.14, 95%CI: (1.02-1.27) per 10 cm 
increase in hip circumference measure was also found to be significant [38]. 
Interestingly, Morimoto et al. [39] found with the Women's Health Initiative 
Observational study that anthropometric measurements (BMI, WHR, waist 
circumference, hip circumference) were not associated with breast cancer risk among 
women who had ever used HRT. But they did find that among non-HRT users, the 
relative risk for postmenopausal breast cancer was 2.52, 95%CI: (1.62-3.93) for women 
with BMI>31.1, compared to slimmer women with BMI ::::: 22.6. Waist circumference and 
hip circumference were both associated with postmenopausal breast cancer risk 
independently among non-HRT users; however, WHR was not associated with 
postmenopausal breast cancer for non-HRT users [39]. 
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Few studies have investigated the association between obesity and breast cancer 
among Hispanic women. However, a study conducted by Wenten et al [40] investigated 
associations between obesity factors and breast cancer risk among Hispanic and non-
Hispanic white women in New Mexico. After stratifying by menopausal status, results for 
BMI for non-Hispanic white women were not statistically significant; however, results 
were consistent with previous literature. Premenopausal women having a BMI 2: 30 
compared to BMI< 22, had a reduced risk for breast cancer, (OR=0.71; 9S%CI: 0.19-
2.63), while postmenopausal women with BMI 2:30 compared to BMI<22, had an 
increased risk, (OR=2.77, 9S%CI: 0.86-8.89). Contrastingly, Hispanic women did not 
demonstrate this divergence in results, suggesting their relationship between obesity and 
breast cancer may be independent of menopausal status. Hispanic women with a BMI2: 
30 had an increased risk for breast cancer regardless of premenopausal (OR=1.64, 
9S%CI: 0.S2-S.11) or postmenopausal (OR=1.32, 9S%CI: 0.47-3.72) status [40]. It has 
been suggested that ethnic differences in these results for pre and postmenopausal breast 
cancer risk could be attributed to the high prevalence of insulin resistance and 
hyperinsulinemia among the Hispanic population [40]. Obese women who are 
premenopausal normally have decreased levels of estradiol and progesterone, which can 
lower breast cancer risk. However, increased insulin levels could counterbalance these 
lower hormone levels among premenopausal obese women. This counterbalance seems 




The data for the proposed study is drawn from the' Four Corners Breast Cancer 
Study' (4-CBCS), a population-based case-control study of breast cancer in Hispanic and 
non-Hispanic white women between the ages of25 and 79 living in the following areas 
of the Southwestern U.S.: Arizona, Colorado, New Mexico, and Utah. The purpose of 
the original study was to investigate the differences between breast cancer incidence rates 
and prevalence of exposures among Hispanic/American Indian women and non-Hispanic 
white women. A secondary objective of the study was to investigate the association of 
candidate SNPs with breast cancer risk. These SNPs were selected based on their 
hypothesized roles in energy balance and obesity and were postulated to influence breast 
cancer risk through estrogen and insulin-related pathways [32]. 
Selection of Case Subjects 
Cases were ascertained through the state tumor registries. The state of Utah 
utilized an electronic rapid case ascertainment system, while the other states used normal 
registry methods. The Utah and New Mexico cancer registries are funded by the National 
Cancer Institute as Surveillance Epidemiology and End Results registries. Colorado and 
Arizona registries are part of the Center for Disease Control National Program of Cancer 
Registries. All primary incident cases diagnosed with in situ or invasive breast cancer 
(ICDO sites C50.0-C50.6 and C50.8-C50.9) between October 1999 and May 2004 and 
with histological confirmation were eligible. Registries provided information on cases 
ethnicity, as well as estrogen and progesterone receptor tumor status for approximately 
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70% of cases [41]. The Generally Useful Ethnic Search System (GUESS) program was 
also utilized to identify Hispanic women included in the study by surname search [42]. 
For Hispanic cases that were initially identified as Hispanic by either surname search or 
from cancer registry records, 82.3% self-reported their ethnicity to be Hispanic at time of 
interview. For Hispanic controls that were identified by surname search only, this 
percentage was lower with 73.2% reported [43] 
Selection a/Control Subjects 
Controls that were selected were frequency matched on ethnicity and 5-year age 
distribution of the cases. Therefore, the control subjects were chosen to ensure that the 
frequency of the matching factors (i.e. ethnicity and age distribution) were the same as 
found in the case group. Controls from Arizona and Colorado were randomly selected 
from a commercial mailing list if under the age of 65 years. For the states of New Mexico 
and Utah, controls under the age of 65 were randomly selected from the New Mexico and 
Utah driver's license lists. In all of the states, those controls 65 years of age and older 
were randomly selected from the Center for Medicare Services lists. 
All women initially selected for the study were screened for eligibility prior to 
study inclusion. During the screening process, subjects were asked to self-identify their 
ethnicity and race and if their self-reported ethnicity/race did not match that of the 
GUESS program, these subjects were determined to be ineligible for study emollment. 
Approximately 12% of cases and 14% of controls were excluded for this reason [41]. All 
participants of the 4-CBCS study signed informed written consent prior to participation. 
A total of 68% of the women contacted actually completed the study. There were a total 
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of 945 Hispanic and 1,671 non-Hispanic white eligible controls that were interviewed in 
the parent study. For cases, a total of 798 Hispanic and 1,527 non-Hispanic White 
women were included as eligible for analyses [41]. The median time from diagnosis to 
interview was 599 days for New Mexico; 671 days for Arizona, 267 days for Utah, and 
540 days for Colorado [41]. 
Data Collection and Description 
The Institutional Review Board for Human Subjects from each institution 
approved the 4-CBCS study. Interviewer-administered computerized questionnaires 
were used by certified and trained interviewers to collect diet and lifestyle data. The 
interviewer training requirements were as follows. After seven audio taped interviews 
were conducted by trained individuals, interviewers were considered certified 
interviewers. All interviews after the initial seven were audio taped for quality control 
procedures and were selected randomly for quality control review. After 10 interviews 
were conducted by each interviewer, one was evaluated, until the interviewer had 
conducted 50 interviews, then one in 20 interviews was reviewed, or one interview per 
month if the interviewer had less than 20 interviews per month were conducted for that 
particular interviewer. The audio tapes were reviewed for the following aspects: 
interviewer behavior, probing, keeping the subject on task, not providing personal 
opinions, interrupting the subject, the reading of questions, and the quality of the data 
collection [41]. 
For Spanish speaking subjects, the questionnaire was translated into Spanish by 
two individuals with an arbitrator. Although the majority of Hispanic women completed 
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their questionnaire in English, the percentages of Hispanic participants that completed 
their questionnaire in Spanish were as follows: 10% for New Mexico site, 32% for 
Arizona, 10% for Colorado, and 46% for Utah site. The 'referent period' for various 
components of the questionnaire was the year prior to date of diagnosis for cases or date 
of selection for controls. The following information was collected through the 
questionnaire: medical history, reproductive history, family history, diet, physical 
activity, use of tobacco, medication use, diabetes history, and weight history- including 
birth weight, weight at ages 15, 30, 50, and referent year. 
Weight was measured at time of interview to the nearest 0.50 lb and height was 
measured to the nearest 0.25 inches. Weight in pounds was then converted to kilograms 
and height in inches was converted to meters. The formula used to calculate BMI was 
weight in kilograms/height in meters2. For BMI at referent year, the following 
international cut-points were used: <25 as normal weight, 25-29.9 as overweight, and 30+ 
as obese. Waist and hip circumferences were measured and recorded at time of interview 
to the nearest 0.5 inches. An extensive diet history questionnaire was used to obtain 
dietary intake data and was adapted to include common foods from the Southwestern area 
of the US [41] . A modified version of the Cross Cultural Activity Participation Survey 
(CAPS) [44] was used to collect physical activity data for activities performed at home, 
work, and during leisure, and for intensity and frequency during referent year and for 
ages 15,30 and 50. For referent year, total MET minutes of activity were also calculated 
and were reported as MET values [41, 45]. 
Menstrual status on the referent date was recorded as follows: (1) I was still 
having periods and not going through menopause or the change of life; (2) I was still 
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having periods but possibly going through menopause or the change of life; (3) I was 
going through menopause or the change oflife; (4) my periods had stopped by 
themselves; (5) I had an operation which stopped by periods; (6) I was still having 
periods and on HRT; (7) I was taking medication that had stopped my periods; (8) I was 
pregnant or my pregnancy ended within 2 months of then or I was nursing. Women were 
coded as pre/perimenopausal if they reported "yes" to answers 1,2,3, or 8 and 
postmenopausal if they answered "yes" to answers 4,5, or 7. Women who were 57 years 
of age or younger at the reference date and who responded "yes" to 6 were classified as 
premenopausal; and women who were older than 57 years at reference date and 
responded "yes" to 6 were classified as postmenopausal. Also, women who were 
classified as postmenopausal were further categorized based on their recent exposure to 
hormones either through use of HRT or from recent menopause experience. "Recent 
hormone exposure" was considered if the subject had used HRT within the past 2 years 
or if they were pre- or peri-menopausal during the two years prior to the referent date, 
while all other postmenopausal women were classified as not recently exposed to 
hormones [41]. 
Genotyping 
Blood samples were collected and DNA was extracted for 75% of the New 
Mexico sample, 76.6% of participants in Arizona, 74.8% of participants in Colorado, and 
93.6% of participants in Utah. Genotyped DNA from the 4-CBCS was used to assay 11 
SNPs from candidate genes; as previously mentioned, these SNPs were selected based 
upon their suspected role in pathways that connect the energy balance and obesity 
association with breast cancer. The IRS 1 (G972R) and ADRB3 W64R (T>C) variant 
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were assayed using the PCR and digestion with BSTN1. The IRS2 G 1 057D, interleukin 6 
SNPs rs 1800797, rs 1800796, and rs2069849 polymorphism were identified using the 
TaqMan assay [32]. Estrogen receptor alpha (ESR1) 351 A>G was genotyped using 
PCR and XbaI restriction. The IGFBP3 -202 C>A substitution was assessed by PCR and 
digestion with Alw211 restriction enzyme. Sex hormone binding globulin (SHBG) 
D327N (G>A) variant was assessed using PCR and digestion with HinfI restriction. 
Vitamin D receptor (VDR) Bsml rs154410 and Fokl (T>C SNP, rsl0735810 were 
assayed using PCR and restriction fragment length polymorphism methods [32]. 
Fifteen markers were identified to characterize genetic admixture. The following 
markers were amplified using PCR and fluorescently labeled primers with the ABI 3700: 
MID94, MIDI42, MID218, MID558, MID577, MID743, MID919, and MID1656. 
Markers MIDI52, MID237, MID856, MID944, and MID1469 were amplified by PCR 
and size fractioned on 3-4% Nusieve agarose gels and visualized using ethidium bromide 
staining. The remaining marker, TSCOOI075 (rs713366) was an anonymous CIT SNP 
that was genotyped using TaqMan assay (ABI Assays, GA, USA) [32]. The calculation 
for genetic admixture was based on a two population model that included European and 
Native ancestry using the program STRUCTURE 2.0 [32,46-47]. 
For this dissertation, the ADRB2 SNPs were assayed using the TaqMan assay 
(Applied Biosystems, Foster City, CA, USA) and were assessed using PCR technology. 
Each 5ul PCR reaction contained 20 ng of genomic DNA, primers, probes, and TaqMan 
Universal PCR Master Mix (containing Amp Erase UNG, AmpliTaq Gold enzyme, 
dNTPs, and reaction buffer). PCR was carried out under the following conditions: 50°C 
for 2 minutes to activate UNG, 95°C for 10 min, followed by 40 cycles of 92°C for 15 
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sec, and 60°C for 1 minute using 384 well duel block ABI 9700. Fluorescent endpoints 
of the TaqMan reactions were measured using an ABI 7900HT sequence detection 
instrument. 
Independent Variables 
The ADRB2 variants were also studied in terms of their genotypes. The suspected 
disease causing variants for the two ADRB2 SNPs are Arg16 (Minor allele A) and Glu27 
(Minor allele G). The homozygous wild types were used as the referent categories. 
Associations for the heterozygote genotypes were analyzed, in conjunction with the 
homozygous variant genotypes. Dominant and recessive model associations for 
rs1042713 (Arg16Gly) and rs1042714 (Gln27Glu) were also investigated. Haplotypes 
between the two ADRB2 polymorphisms were analyzed as well. 
Dependent Variable 
Breast cancer diagnosis for this study includes all incident invasive or in situ 
breast cancer cases from the 4-CBCS. 
Confounding Variables 
Various risk factors have been found to be historically associated with breast 
cancer, among other risk factors that are believed to contribute to disease risk. It is 
important to consider these risk factors as potential confounders or covariates, and to 
adjust for those found to be significant in analyses. The cases and controls have already 
been frequency matched based upon ethnicity and 5 year age group. Other adjustments 
should be considered for the following variables based on their relevance in the previous 
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literature cited within this proposal. Age was analyzed as a continuous variable. As 
previously mentioned, the two ethnic/racial groups within this study are non-Hispanic 
whites and Hispanics. Education level, which can be used as a surrogate marker for 
socio-economic status, was categorized as the following: high school or less, some 
college, bachelor degree or higher. Aspirin usage is coded as 'Yes or No' based upon the 
question: Before referent year did you ever take aspirin on a regular basis?" NSAID 
usage is also coded as 'Yes or No' based upon the question: Before referent date did you 
take non-steroidal anti-inflammatory drugs on a regular basis? Height was measured to 
the nearest 0.25 inches and was converted to centimeters. The formula used to calculate 
BMI was weight in kilograms/height in meters2. For BMI at referent year, the following 
international cut-points were used: <25 as normal weight, 25-29.9 as overweight, and 30+ 
as obese. Waist and hip circumferences were measured and recorded at time of interview 
to nearest 0.5 inches. WHR was categorized as <0.8, 0.8-0.9, and >0.9. Waist 
circumference was converted to centimeters, and was categorized into quartiles based 
upon the distribution of the data: <77.7, 77.7-86.5, 86.6-97.7, and ~97.7. Age at 
menarche was categorized by the following age groups: <12,12,13, and 14 plus. 
Menopausal status was analyzed in two groups consisting of pre/peri-menopausal and 
postmenopausal women based upon the algorithm previously described. Parity was 
categorized in the following groups: nulliparous, 1-2, 3-4, and 5 plus. Smoking status was 
categorized as current smoker, former smoker, never smoked regularly OR ever smoked 
vs. never smoked. Physical activity was measured by the total METs. METs are defined 
as the metabolic equivalent of the task and were calculated based upon the amount, 
intensity, and duration of activities performed during the referent year. The METs were 
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then assigned to each activity based on the Compendium of Physical Activities [48]. 
The variable used for analysis is total MET hrs/week= (total MET hours/week of 
moderate physical activity + total MET hours/week of vigorous physical activity) and 
was analyzed as a continuous variable. Caloric/energy intake per day was analyzed as a 
continuous variable. Family history of breast cancer 'Yes or No' was based upon a family 
history of breast cancer in a first degree relative, i.e. parent, sibling, or offspring. 
Diabetes history was categorized as 'Yes', 'borderline', or 'No' based upon the question 
"Ever told before referent date that you had diabetes or high blood sugar?" Specific cut-
points for those variables that are categorized are based upon previous literature from the 
4-CBCS study. The percentage of genetic admixture was analyzed as a continuous 
covariate based on the genotypes for ancestry-informative markers previously collected 
with the parent study [32]. Bias from genetic admixture is possible in studies with 
populations that have a mixture of genetic heritage from one population with low 
incidence of a disease and a second with high incidence. As a result, a polymorphism that 
is more common in the high incidence population can appear to be associated with 
disease in the admixed population, when in actuality there is no causal association [32, 
49]. Study site, also known as center, was also included as a covariate to help control for 
different proportion of cases and controls interviewed at each center [27, 32, 41]. 
Methods of Data Analyses 
Cohort Description 
Data analysis was performed using SAS version 9.2 (SAS Institute, Cary NC). 
Descriptive statistics were calculated for all covariates. The following descriptive 
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statistics were reported for continuous covariates such as age, BMI, height, WHR, waist 
circumference, total METs, and calories consumed: mean, standard deviation, and p-
values for t-tests. These reports were calculated for the overall sample as well as between 
cases and controls. The categorical variables (such as ethnicity, education, age 
categorized at menarche, aspirin use, NSAID use, parity, menopausal status, recent 
estrogen use, family history, BMI-category, WHR-category, WC-category, cigarette 
smoking status, and other previously mentioned insulin/obesity related variants) were 
reported as frequencies, percentages, as well as by case-control status and ethnicity. For 
the case- control comparison, the Mantel-Haenszel Chi-Square test was utilized to test for 
significant differences between the two groups. 
Genotype distributions of the SNPs rsl042714 (Gln27Glu) and rsl042713 
(Arg16Gly) were also conducted for the total sample and by case vs. control status by 
ethnicity. Frequencies and percentages were reported, in addition to p values calculated 
by the Pearson chi-square test to test for significant differences between the two groups. 
Genotype distributions were also evaluated for agreement with Hardy-Weinberg 
equilibrium (HWE) by the Pearson chi-square test among controls. 
Finding Predictors and Logistic Regression 
Univariable analyses was conducted using logistic regression to test all potential 
confounders with a significance level ofp value (alpha level) :s 0.20, with final models 
including variables with significance levels ofp<O.OS. The univariable analyses were also 
stratified by ethnicity. The model used was an unconditional logistic regression model 
because the controls are not fully matched with the cases. 
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Letp= probability of being case; and po = (l-p) = probability of being control; 
logit (P) = log (Pll-p) 
Example ofunivariable model: logit(p) = bo+ b,X; with X=covariate(s) of interest 
A multivariable model was constructed using logistic regression and confidence 
intervals were reported based upon the significant univariable predictors. Those deemed 
as covariates were adjusted for in the multivariable logistic regression models after 
comparing the log likelihood of each model with and without the covariates of interest 
and the percent of change between the point estimates. Genotype and haplotype 
association tests for SNPs rsl042714 (Gln27Glu) and rsl042713 (Arg16Gly) were 
reported as crude odds ratios (ORs), 95% Confidence Intervals (CIs) determined by 
unconditional logistic regression. Genotype and haplotype association tests for the same 
SNPs were then reported with adjusted ORs and CIs that were adjusted for significant 
covariates from the univariable and multivariable analyses. Codominant models were 
first analyzed, evaluating the ADRB2 SNPs as a three-level categorical variable; these 
codominant models are dependent upon the rarity of the variant genotype. Dominant 
models (homozygous wild type vs. heterozygous + homozygous variant) were also used 
comparing the variant carriers with the referent homozygous wild type. Recessive models 
(homozygous wild type + heterozygous vs. homozygous variant) were computed to 
compare the homozygous variant with all other genotypes for that SNP. 
The multivariable logistic regression model was based on the following: 
logit{p) 
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Example of full model with all covariates of interest: 
Logit(p)= bo+ bJ(rsl042713 (Arg16Gly) [GIG +G/A vs. AlA) + b2(age) + b3(ethnicity) + 
b4(education) + bs(aspirin usage) + b6(NSAID usage) + b7(height) + bs(BMI) + b9(WHR) 
+ bJO(WC) +bJJ(menstruation start age) + bdmenopausal status) +bl3(age at first birth) + 
b J4(smoking) + bJs(physical activity)+ b J6(caloric intake) + b17(family history) + 
bJs(diabetes) + b J9(IRS-l) + b20(IRS-2) ... bk(Xk) 
(Note: the full model has all covariates of interest, however, variables highly correlated, 
such as height and BMI, were not modeled together, and only one of the significant 
covariates, i.e. BMI, from the univariable analyses were used for multivariable 
modeling). 
Haplotype analysis for ADRB2 SNPs rsl042714 (Gln27Glu) and rsl042713 
(Arg16Gly) was conducted using PROC Haplotype in SAS. A haplotype is defined as a 
combination of alleles at multiple loci on a single chromosome and a pair of haplotypes 
comprises the multi locus genotype. Using the expectation-maximization (EM) 
algorithm, SAS generates the maximum likelihood estimates of haplotype frequencies 
based on the multilocus sample of the genotypes under the Hardy-Weinberg equilibrium 
(HWE) assumption. With the Linkage Equilibrium method for initialization to estimate 
haplotype frequencies, SAS outputs all the haplotype combinations, for each individual 
as probability scores based on their genotypes. These probabilities are used in regression 
models with epidemiological association studies. Haplotype probabilities that were 
unambiguously resolved were categorized into haplotype dose variables for each subject. 
Individuals with ambiguous haplotypes were those who were not genotyped for one of 
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the SNPs. These individuals were excluded from haplotype analyses (n= 191). Values of 
haplotype dose are listed as follows: "0" equaling zero copies, indicating this haplotype is 
not possible for this individual, "1" equaling one copy, indicating heterozygosity at one 
marker, and "2" equaling two copies, indicating homozygosity for the haplotype [33, 50]. 
Multiplicative interaction models were used to determine the statistical 
interactions between the 2 SNPs of interest and significant haplotypes with the 
hypothesized effect modifiers including family history, ethnicity, obesity, menopausal 
status, and functional SNPs in the following insulin/obesity related genes: IRS 1, IRS2, 
IOF1, ADRB3, and IL6 variants. 
Example: logit (P) = bo + b I (ADRB2 SNP) + b2 (BMIIobese) +b3 (SNP x BMIIobese) 
The presence of interaction was tested using the chi-square p-value for interaction < 0.05. 
The formal test for interaction between the variables of ethnicity and 
polymorphisms/haplotypes was evaluated using the difference in maximum likelihood 
estimates for logistic regression models with and without the constructed ethnicity 
specific- polymorphism/haplotype variable, using a chi-square test with two degrees of 
freedom. The test for effect modification using specific strata for potential effect 
modifiers may have been limited by the sample size, but included stratification by 
ethnicity, obesity, history of diabetes, and recent hormone exposure. An informal test of 
interaction was conducted by performing this type of stratification to evaluate if odds 
ratios differed between the strata for each hypothesized effect modifier. P values for 
heterogeneity were calculated for differences in association between non-Hispanic white 
and Hispanic women by comparing the difference in maximum likelihood estimates for a 
logistic regression model with and without an interaction term between ethnicity and the 
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genotype/haplotypes of interest using a chi-square test with one degree of freedom. 
Multinomial regression models were used to evaluate the associations of the tumor 
characteristics of ER status. 
Multinomial Regression Equation: 
Where po= (0) control, p 1= (1) ER (+) case, and P2= (2) ER (-) case 
X j= ADRB2 SNP/haplotype and X2 ... = other covariates 
logit (PI) = bo + b l (ADRB2 SNP) + b2X2 .. · 
logit (P2) = bo + b l (ADRB2 SNP) + b2X2 ... 
Sample Size and Statistical Power Calculation 
Power calculation was determined with the sample size ofN=3,908; cases=I,850 
(1,244 non-Hispanic white, 606 Hispanic) and controls= 2,058 (1,330 non-Hispanic 
white, 728 Hispanic). Equations for Sample size for 2 Binomials were used, where po= 
the number of controls with the genotype of interest (ex. AI A) divided by the total 
number of controls, and PI = the number of cases with the genotype of interest (ex. AlA) 
divided by the total number of cases [51]. For a specific example the variant rsl042713 
(ArgI6Gly) will be used. The suspected disease causing genotype using the recessive 
model for rs1042713 (ArgI6Gly) is the AlA genotype. The AlA genotype will be denoted 
as '2', the GI A genotype will be denoted as '1 ' , and GIG genotype will be denoted as '0'. 
For the dominant model, 0 vs. 1 +2 scheme will be assessed, where 1 +2= G/A +A/A vs. 
O=G/G. As previously mentioned, for controls po = proportion of AI A, therefore 1- Po = 
G/A+G/G in controls. And for cases PI = proportion of AlA, therefore 1- PI = G/A+G/G 
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in cases. Conversely, power calculations for the recessive models will be determined, 
using the 0+ 1 vs. 2 scheme, with 0+ 1 = GIG +GI A and 2=AI A. For controls po = 
proportion of AlA + GI A, therefore 1- po = proportion of GIG in controls. And for cases 
PI = proportion of A/A+G/A, therefore 1- PI = proportion of GIG in cases. 
Under the null hypothesis, we assumed these two proportions are equal, i.e. Ho: 
PO=Pl Under the alternative hypothesis, we assumed that the minor allele homozygous 
genotype causes breast cancer, therefore under Ha: PI> Po. There are three approaches for 
comparing these two hypotheses: 1) based on difference between the proportion, where 
PI-PO; 2) based on relative risk where Pl/po; or 3) based on odds ratio where [pill-pdl 
[poll-po]. For power calculation purposes, the relative risk (RR= Pl/po) approach was 
used. 
In published literature and online sources [52], the frequency of the minor alleles 
of interest are available, however, we needed to find the frequency of the genotypes to 
estimate the distribution of these genotypes in our population or sample of women. In 
order to calculate po and PI, the incidence of breast cancer in the general population is 
also of importance and was found by an online source provided by the SEER data [53]. 
See Example below: 
Example using variant rs1042713 (Arg16Gly), with minor allele 'A' frequency 
(MAF) = 0.325 from data collected from HapMap.org [52] ; frequency of2 
genotype=A/A= (0.325 x 0.325)= 0.106; Total Sample= 3,908 (cases= 1,850, controls= 
2,058). 
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Displayed below are the calculations for RR=I.5 when model= '0+ 1 vs. 2'. We are 
assuming the controls represent the standard popUlation. 
Equation 1: Wo Po + WIPI= 0.106; with Wo= I-wI 
wI=incidence of breast cancer from general population according to SEER [53] 
wI=0.12 weight for cases; and Wo= 0.88 weight for controls 
Equation 2: RR=I.5= PI/ Po; therefore 
Using Equation 1: 0.88po+ 0.12(1.5po) = 0.106 
0.88 po+ 0.183po = 0.106 
1.06po = 0.106 
Therefore po= 0.10 and PI= (0.10)1.5= 0.15. 
Table 1 A and B display the distribution of genotypes and po, PI values for ADRB2 when 
RR=1.2, 1.5, and 1.75. 
Table lA and IB 
A. Proportion Values for Recessive Model "0+1 vs. 2" 
SNP Minor Freq Freq Freq "Ovs.I+2" 
Allele GIG=O GIA=1 AIA=2 1.2 1.5 1.75 
Freq 
Po PI Po PI Po PI 
rs I 042713 0.325 0.456 0.439 0.106 0.10 0.12 0.10 0.15 0.10 0.17 
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B. Proportion Values for Dominant Model "0 vs. 1+ 2" 
SNP Minor Freq Freq Freq "0 +1 VS. 2" 
Allele GIG=O GIA=I A/A=2 1.2 1.5 1.75 
Freq 
Po PI Po PI Po PI 
rs I 042713 0.325 0.456 0.439 0.106 0.53 0.64 0.51 0.77 0.50 0.87 
From the PI and po values calculated for ADRB2 SNPs rs1042714 (Gln27Glu) 
and rs 1 042713 (Arg 16Gly) , the power estimates presented were calculated by formulas 
utilized by OpenEpi.com [54]. 
The equations used to calculate the power percentages for this project are based 
on the continuity-corrected arc sine transformation, since the comparisons are between 
two independent proportions [55]. This method works well with smaller samples and is 
better for precision. If Ai is the binomially distributed random variable with sample size 
ni and Pi is the parameter, and i=O or 1, the distribution of the arc sine transformation can 
be approximated with sin-I~( X/ ni) ~N(sin-I~(pi 114 ni)' Using the Ho: PO=PI against the 
alternative hypothesis, Ha: PI> po, with equal sample sizes and a significance level a and 
power l-~, n can be estimated as follows: n= Yz{(ZI_a-Zp)/ sin-I~ po- sin-I~ PI)} 2[55]. For 
an accurate estimate of power, the continuity-corrected version of the arc sine 
transformation can be used: (ZI_a-Zp)2= 2n{ sin-I~(po-1I2n)- sin-I~(pl+1I2n)}2 [55]. A 
final equation can be derived for sample size n= {Z+ ~(Z2 + 2C~)}2/8~2; where Z=(ZI_a-
Zp), ~=( sin-I~ po- sin-I~ PI) and c={(POqOrl + (Plqlr I/2 } [55]. OpenEpi was another 
method used to calculate the power for this project. The following equation was used by 
OpenEpi to calculate the power using the power with continuity correction method [54]: 
29 
Where n' = n I - [( K + 1) I ( K . L1)]; 
Tables 2A and B display the power percentages for the overall sample based upon 
the Po, PI values for the 2 SNPs of interest when RR=1.2, 1.5, and 1.75. 
Tables 2A and B 
A. Power Analysis for 4-CBCS (n=3,908) for Recessive Model "0+ 1 vs. 2" 
SNPs MAF2 Model: "0 +1 vs. 2" 
RR= 1.2 RR= 1.5 
poJ pl-i Power Po PI Power 
ADRB2 
rs1042713 0.325 0.10 0.12 0.52 0.10 0.15 0.99 
ADRB2 
rs1042714 0.467 0.21 0.26 0.89 0.21 0.31 1 
I, - - -0- homozygous WIld type, 1- heterozygous, 2- homozygous varIant 










4 PI= the estimated proportion of cases with variant of interest calculated from Equation 1 
and Equation 2. 
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B. Power Analysis for 4-CBCS (n=3,908) for Dominant Model "0 vs. 1 + 2" 
SNPs MAF2 Model: "0 vs.l + 2"/ 
RR= 1.2 RR= 1.5 RR= 1.75 
Po PI Power Po PI Power Po PI Power 
ADRB2 
rslO42713 0.325 0.53 0.64 1 0.51 0.77 1 0.50 0.87 
ADRB2 
rsl042714 0.467 0.70 0.84 1 0.68 1.01 1 0.66 1.15 
/, - - -0- homozygous wIld type, 1- heterozygous, 2- homozygous van ant 
2 MAF= Minor allele frequency from Hapmap.org.[S2] 
3 po= the estimated proportion of controls with variant of interest calculated from 
Equation 1. 
4 PI = the estimated proportion of cases with variants of interest calculated from Equation 





A total of2,574 non-Hispanic white (NHW) (n=1,244 cases, n=1,330 controls) 
and 1,334 Hispanic women (n=606 cases, n=728 controls) were included in analyses. 
Characteristics of the study population by ethnicity and case-control status are shown in 
Table 3. The majority of women were over the age of 50 years at time of diagnosis, and 
there was a significant difference between the mean age for Hispanic cases compared to 
Hispanic controls (p=0.03), with the mean ages of 52.6 years and 54.0 years, 
respectively. There was also a significant difference for aspirin usage between Hispanic 
cases and controls (p=0.03), as more controls reported history of aspirin use, 142 controls 
compared to 91 cases. Average body mass index was also significantly different among 
Hispanics cases and controls (p=O.OI), as Hispanic cases were slightly less overweight 
(mean BMI= 28.1 kg/m2 for cases compared to mean BMI=29.0 kg/m2 for controls). 
Family history with a 1 sl degree relative was significantly different between ethnic 
groups, as more NHW women reported a family history of breast cancer compared to 
Hispanics. Results for family history were also significantly different within both ethnic 
groups comparing cases vs. controls (Hispanics p=O.OI; NHW p= <0.01). With the 
exception of age at menarche and recent estrogen use, all other covariates were 
significantly different when comparing Hispanic women to NHW. The majority of 
Hispanic women only had some high school or less and a larger proportion was diabetic 
or borderline diabetic, compared to NHW. 
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Table 3. Characteristics of Study Population, Stratified by Ethnicity and Case-Control Status, 4-Corners Breast Cancer Study, 
1999-2002 (n=3,908). 
Non-Hispanic White (n=2,574) Hispanic (n= 1,334) 
Case Control Case Control 
No. % No. % p value a No. % No. % p value 
a p value b 
Total Subjects 1244 1330 606 728 
Center 0.08 0.33 <0.001 
Arizona 171 13.6 263 19.8 123 20.3 164 22.5 
Colorado 257 20.7 218 16.4 120 19.8 132 18.1 
New Mexico 494 39.7 496 37.3 263 43.4 251 34.5 
Utah 322 25.9 353 26.5 100 16.5 181 24.9 
Education level 0.21 0.05 <0.001 
High school or less 310 24.9 353 26.5 348 57.4 390 53.6 
Some college 459 36.9 499 37.5 172 28.4 203 27.9 
U-l Bachelor degree! higher 475 38.2 478 35.9 86 14.2 135 18.5 
U-l 
Age at menarche, years 0.01 0.45 0.648 
<12 255 20.5 235 17.7 137 22.6 148 20.3 
12 332 26.7 352 26.5 160 26.4 187 25.7 
13 349 28.1 349 26.2 127 21.0 179 24.6 
14+ 308 24.8 394 29.6 182 30.0 214 29.4 
Aspirin Usage g 0.21 0.03 <0.001 
Yes 279 22.4 326 24.5 91 15.0 142 19.5 
No 965 77.6 1004 75.4 515 85.0 586 80.5 
NSAID Usage 
h 
0.84 0.06 <0.001 
Yes 388 31.2 410 30.8 142 23.4 203 30.2 
No 856 68.8 920 69.2 464 76.6 525 69.8 
Parity <0.001 0.07 <0.001 
Nulliparous 210 16.9 188 14.1 57 9.4 70 9.6 
1-2 543 43.7 541 40.7 247 40.8 251 34.5 
3-4 400 32.2 458 34.4 217 35.8 285 39.2 
5+ 91 7.3 143 10.8 85 14.0 122 16.8 Table Cant. 
Non-Hispanic White (n=2,574) Hispanic (n= 1,334) 
Case Control Case Control 
No. % No. % p value a No. % No. % p value 
a p value b 
Total Subjects 1244 1330 606 728 
Menopausal status 0.07 0.20 <0.001 
Pre-/Peri-menopausal 430 34.6 415 31.2 243 40.1 267 36.7 
Post-menopausal 814 65.4 915 68.8 363 59.9 461 63.3 
Recent estrogen use d 0.04 0.23 0.1043 
Yes 992 79.7 1016 76.4 468 77.2 542 74.5 
No 252 20.2 314 23.6 138 22.8 186 25.6 
Family history, 1st degree <0.001 0.01 0.0045 
Yes 277 22.5 201 15.4 107 18.0 90 12.7 
No 952 77.5 1106 84.6 486 82.0 617 87.3 
Diabetes history 0.42 0.71 <0.001 
Vol Yes 91 7.3 113 8.5 90 14.9 110 15. I 
~ Borderline 22 1.8 15 I.I 12 2.0 21 2.9 
No 1130 91.0 1200 90.4 504 83.2 596 82.0 
Body mass index (kg/m2) c 0.30 0.06 <0.001 
<25 578 46.5 601 45.4 198 32.7 204 28.1 
25-29.9 370 29.7 379 28.6 212 35.0 259 35.7 
30+ 296 23.8 345 26.0 196 32.3 263 36.2 
Waist- Hip- Ratio (WHR) 0.44 0.85 <0.001 
<0.8 646 51.9 707 53.2 162 26.7 199 27.3 
0.8 to 0.9 484 38.9 511 38.4 347 57.3 413 56.7 
>0.9 114 9.2 112 8.4 97 16.0 116 15.9 
Waist circumference (cm.) 0.17 0.46 <0.001 
<77.7 368 29.9 427 32.8 95 16.0 114 15.9 
77.7-86.5 301 24.5 315 24.2 168 28.3 184 25.7 
86.6-97.7 296 24.0 289 22.2 170 28.6 213 29.8 




Non-Hispanic White (n=2,574) Hispanic (n= 1,334) 
Case Control Case Control 
No. % No. % p value a No. % No. % p value 
Total Subjects 1244 1330 606 728 
Cigarette smoking statusi 0.12 0.45 
Current smoker 154 12.4 163 12.3 70 11.6 92 12.6 
Former smoker 391 31.4 365 27.4 128 21.1 159 21.8 
Never smoked 699 56.2 803 60.4 408 67.3 477 65.5 
Mean (sd) Mean (sd) E value e Mean (sd) Mean (sd) p value 
Age (yrs) 55.4 11.0 56.2 12.2 0.09 52.6 Il.l 54.0 12.0 0.Q3 
Body mass index (kg/m2) c 26.8 6.0 27.0 6.2 0.62 28.1 6.0 29.0 6.2 0.01 
Waist circumference (cm.) 87.1 14.6 86.6 15.0 0.41 90.9 14.2 91.8 14.6 0.25 
Waist-hip ratio 0.80 0.07 0.80 0.07 0.12 0.84 0.06 0.84 0.07 0.54 
Height (cm.) 163.3 6.32 162.8 6.42 0.07 157.3 6.30 157.0 6.34 0.47 
Total MET min/wk 1430 1738 1486 1816 0.43 1312 1940 1233 1754 0.44 
Calories (kcal) 2180 1032 2101 984 0.05 2737 1414 2684 1439 0.50 
Note: Percentages may not add up to 100 due to rounding. 
a Case-control comparison within ethnicity. Mantel-Haenszel chi-square p values from chi-square tests. 
b Ethnic group comparison, regardless of case-control status. Mantel-Haenszel chi-square p values from chi-square tests. 
C Body mass index (BMI) calculated as kilograms (kg)/meters (mi. 
e 










d Recent hormone exposure, within 2 yrs of referent year (one year prior to date of diagnosis for cases and one year prior to date of 
selection for controls). 
e Case-control comparison within ethnicity. p values from t-tests. 
f Ethnic group comparison, regardless of case-control status. p values from t- tests. 
g Aspirin use based on question: Before referent year did you ever take aspirin on a regular basis? 
" Non-steroidal anti-inflammatory drugs (NSAID) use based on question: Before referent date did you take non-steroidal anti-
inflammatory drugs on a regular basis? 
Cigarette smoking status based on several factors including if subject ever smoked 100 cigarettes per day or more and if subject 
smoked regularly during the referent year. 
b 
Table 4. Test for Hardy Weinberg Equilibrium CHWE) by Ethnicity among 
Controls for ADRB2 SNPs from the 4-Corners Breast Cancer Study 
ADRB2 
SNPs Non-Hispanic White Hispanic 
Hetero- Allelic HWE Hetero- Allelic 
zygosity Diversity p- value zygosity Diversity 
rs1042713 0.4566 0.4643 0.4098 0.4912 0.4918 
rs1042714 0.4820 0.4905 0.3850 0.3550 0.3560 






Hardy Weinberg Equilibrium for each ethnic group was calculated based on the 
frequency of the two ADRB2 polymorphisms among controls. As demonstrated in Table 
4, all p values for Hispanic and NHW women are greater than 0.05 for both SNPs. With 
the use of the Haplotype Procedure in SAS, three haplotypes were identified between 
rsl042713 (Arg16Gly) and rsl042714 (Gln27Glu). The estimated haplotype frequencies 
based on the study population are as follows: A-G, 0.392; G-C, 0.362; G-G, 0.246. The 
A-C haplotype yielded an estimated frequency of 0, and was not analyzed further. The 
method for calculating the actual haplotype frequencies among the sample has been 
previously discussed. (See Methods) 
The distributions of the two ADRB2 polymorphisms and haplotypes evaluated are 
shown in Table 5 along with the other genetic markers previously collected for the 
4-CBCS. The table is also stratified by ethnicity and case-control status. There was a 
significant difference between ethnic groups for both ADRB2 polymorphisms, however, 
genotype proportions did not differ between cases and controls for Hispanics or NHW. 
Hispanic women did have a slightly higher proportion of the rsl042713 (Arg16Gly) AlA 
variant genotype compared to NHW, while NHW women had a higher proportion of the 
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rs1042714 (Gln27Glu) GIG variant genotype. Interestingly, a large proportion ofNHW 
women had 0 copies of the G-G haplotype compared to Hispanic women and a large 
proportion of Hispanic women had 0 copies of the G-C haplotype compared to NHW. 
The only polymorphisms within this study that differed by case-control status are found 
among NHW women and they are IL6 SNPs rs1800797, rs1800796, rs1800795, and 
rs2069832. 
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Table 5. Genotype Characteristics of Study Population, Stratified by Ethnicity and Case-Control Status, 4-Corners Breast 
Cancer Study, 1999-2002 (n=3,908). 
Non-Hispanic White (n=2,574) Hispanic (n= 1,334) 
Case Control Case Control 
No. % No. % p value a No. % No. % p value a p value b 
Total Subjects 1244 1330 606 728 
ADRB2 (rslO42713) 
Genotype 0.90 0.41 <0.001 
GIG, homozygous wild type 499 41.3 520 39.8 236 30.5 236 33.0 
GI A, heterozygous 535 44.3 613 46.9 346 50.1 346 48.3 
AI A, homozygous variant 174 14.4 173 13.3 115 19.5 134 18.7 
ADRB2 (rsI042714) 
Genotype 0.62 0.50 <0.001 
CIC, homozygous wild type 403 33.0 427 32.6 359 60.4 415 58.0 
GIC, heterozygous 591 48.4 629 48.0 202 34.0 263 36.7 
w GIG, homozygous variant 226 18.5 255 19.5 33 5.6 38 5.3 00 
ADRB2 Haplotype A-G 
o copies 539 43.3 548 41.2 0.67 197 32.5 250 34.3 0.54 <0.001 
1 copy 531 42.7 609 45.8 294 48.5 344 47.3 
2 copies 174 14.0 173 13.0 115 19.0 134 18.4 
ADRB2 Haplotype G-G 
o copies 815 65.5 851 64.0 0.77 275 45.4 330 45.3 0.65 <0.001 
1 copy 371 29.8 446 33.5 275 45.4 319 43.8 
2 copies 58 4.7 33 2.5 56 9.2 79 10.9 
ADRB2 Haplotype G-C 
o copies 440 35.4 452 34.0 0.40 374 61.7 429 58.9 0.43 <0.001 
1 copy 578 46.5 623 46.8 199 32.8 261 35.9 
2 copies 226 18.2 255 19.2 33 5.5 38 5.2 
Table Cont. 
Non-Hispanic White (n=2,574) Hispanic (n= 1,334) 
Case Control Case Control 
No. % No. % p value a No. % No. % p value a p value b 
Total Subjects 1244 1330 606 728 
ADRB3 (W64R; Trp>Arg) 
Genotype 0.49 0.14 <0.001 
WW, homozygous wild type 1056 85.8 1123 84.6 441 73.0 552 76.1 
WR, heterozygous 166 13.5 196 14.8 146 24.2 159 21.9 
RR, homozygous variant 9 0.8 8 0.6 17 2.8 14 1.9 
Androgen Receptor 
Genotype 0.76 0.14 <0.001 
WW, homozygous wild type 308 25.0 344 26.1 226 37.7 309 43.0 
WR, heterozygous 596 48.5 623 47.2 278 46.3 298 41.5 
R~ homozygous variant 326 26.5 352 26.7 96 16.0 112 15.6 
Insulin Receptor Substrate -
w IRSI (G972R) Genotype 0.99 0.25 <0.001 \0 
GIG, homozygous wild type 1076 87.1 1154 87.0 542 89.7 666 91.6 
G/R, heterozygous 155 12.5 169 12.7 60 9.9 59 8.1 
RlR, homozygous variant 5 0.4 4 0.3 2 0.3 2 0.3 
Insulin Receptor Substrate -
IRS2 (GI057D) Genotype 0.09 0.91 <0.001 
GIG, homozygous wild type 525 42.3 544 41.0 224 37.0 263 36.2 
GIO, heterozygous 578 46.6 594 44.7 276 45.6 347 47.7 
DID, homozygous variant 138 11.1 190 14.3 105 17.4 117 16.1 
Estrogen Receptor 
(ESRl_Xba) 0.92 0.84 <0.001 
xx site present 518 42.1 564 42.5 303 50.2 351 48.4 
Xx het 561 45.6 600 45.2 244 40.4 313 43.2 
XX site absent 151 12.3 164 12.4 57 9.4 61 8.4 
Table Cont. 
Non-Hispanic White (n=2,574) Hispanic (n= 1,334) 
Case Control Case Control 
No. % No. % p value a No. % No. % E value 
a 
p value b 
Total Subjects 1244 1330 606 728 
Insulin Growth Factor-l 
(lGF-l) 0.23 0.60 0.045 
CA-191I9 509 41.7 575 43.6 236 39.3 297 41.3 
19/non-19 556 45.6 594 45.0 279 46.4 319 44.4 
Non-19/non-19 155 12.7 150 11.4 86 14.3 103 14.3 
Insulin Growth Factor 
Binding Protein-3 (IGFBP3) 0.67 0.09 <0.001 
CIC, homozygous wild type 351 28.5 384 29.0 226 37.4 317 43.9 
AIC, heterozygote 608 49.4 658 49.6 305 50.5 318 44.0 
AI A, homozygous variant 273 22.2 284 21.4 73 12.1 88 12.2 
Sex Hormone Binding 
Globulin (D327N) 0.42 0.20 <0.001 
+:- DID, homozygous wild type 944 76.8 1043 78.5 510 84.3 624 86.1 
0 
DIN, heterozygote 271 22.1 266 20.0 88 14.6 99 13.7 
NIN, homozygous variant 14 1.1 19 1.4 7 1.1 2 0.3 
Vitamin D receptor Bsml 0.62 0.15 <0.001 
O-bb, site present 422 34.1 478 36.0 299 49.5 386 53.6 
I-bB, heterozygote 616 49.8 632 47.6 249 41.2 275 38.2 
2-BB, site not present 198 16.0 219 16.5 56 9.3 59 8.2 
Vitamin D receptor Poly-A 
tail 0.44 0.23 <0.001 
O-LL 433 35.6 491 37.2 302 50.6 397 55.1 
I-SL heterozygote 583 47.9 617 46.8 244 40.9 260 36.1 
2-SS short variant 201 15.5 211 16.0 51 8.5 63 8.8 
Vitamin 0 receptor Fokl 0.72 0.54 0.001 
0-ff (2 start sites) 179 14.5 188 14.2 101 16.7 128 17.7 
I-fFhet 565 45.9 632 47.6 292 48.3 353 48.7 
2-FF (T>C polymorphism) 488 39.6 508 38.3 212 35.0 244 33.7 Table Cont. 
Non-Hispanic White (n=2,574) Hispanic (n= 1,334) 
Case Control Case Control 
No. % No. % p value a No. % No. % p value a p value b 
Total Subjects 1244 1330 606 728 
IL6 (rsI800797) 0.003 0.63 <0.001 
O-wildtype 464 37.7 427 32.3 411 67.9 468 64.6 
I-heterozygote 573 46.5 648 49.0 164 27.1 233 32.2 
2-homozygous variant 195 15.8 248 18.8 30 5.0 23 3.2 
IL6 (rs 1800796) 0.02 <0.001 
O-wildtype 1074 86.5 1188 89.4 351 58.0 406 55.9 0.60 
I-heterozygote 161 13.0 137 10.3 209 34.6 268 36.9 
2-homozygous variant 6 0.5 4 0.3 45 7.4 52 7.2 
IL6 (rsI800795) 0.003 0.49 <0.001 
O-wildtype 455 36.8 409 30.8 404 66.8 460 63.4 
I-heterozygote 570 46.1 661 49.7 171 28.3 239 32.9 
~ 2-homozygous variant 212 17.1 259 19.5 30 5.0 27 3.7 
IL6 (rs2069832) 0.002 0.51 <0.001 
O-wildtype 450 36.5 406 30.7 400 66.3 457 63.0 
I-heterozygote 577 46.8 660 49.9 172 28.5 241 33.2 
2-homozygous variant 207 16.8 258 19.5 31 5.1 28 3.9 
IL6 (rs2069849) 0.85 0.23 <0.001 
O-wildtype 1181 95.4 1268 95.6 539 89.1 632 87.2 
I-heterozygote 56 4.5 58 4.4 66 10.9 91 12.6 
2-homozygous variant 0.1 0.1 0 0 2 0.3 
Note: Percentages may not add up to 100 due to rounding. 
a Case-control comparison within ethnicity. Mantel-Haenszel chi-square p values from chi-square tests. 
b Ethnic group comparison, regardless of case-control status. Mantel-Haenszel chi-square p values from chi-square tests. 
Table 6. Characteristics of the ADRB2 Polymorphisms 
SNP Alleles Allele Change Residue Change Amino Acid 
Name 
rsl042713 Major: G AGA~ GGA R [Arg] ~ G [Gly] Arg16Gly 
Minor: A 
rsl042714 Major: C CAA~GAA Q [Gln] ~ E [Glu] Gln27Glu 
Minor: G 
Reference: [2] 
(Note: Gin-Glutamine, Glu-Glutamic Acid) 
Table 6 reports the amino acid changes associated with the major and minor 
alleles for each ADRB2 polymorphism. Based on this table, the following amino acids 
are associated with each haplotype: (G-G) haplotype-Gly-Glu; (A-G) haplotype-Arg-Glu; 
(G-C) haplotype-Gly-Gln; and (A-C) haplotype- Arg-Gln (not discussed). 
Univariable Odds Ratios (ORs), 95% Confidence Intervals (95%CI) and p values 
are reported for all descriptive covariates and were further stratified by ethnicity in Table 
7. Significant covariates with breast cancer association were identified with p values :s 
0.20. The following characteristics were suggested for multivariable models: age at 
menarche, parity, family history of breast cancer, recent hormone exposure, aspirin use, 
smoking status, and body mass index at referent year. History of diabetes was also 
included in multivariable modeling as it is related to the ADRB2 gene and risk of breast 
cancer. The univariable odds ratios stratified by ethnicity were comparable for Hispanic 
and NHW, except for history of diabetes [Hispanic OR=0.68; 95% CI: 0.33-1.39 vs. 
NHW OR= 1.56; 95%CI: 0.80-3.02]. 
Table 8 reports the univariable results for the ADRB2 polymorphisms, ADRB2 
haplotypes, and the other polymorphisms collected for the 4-CBCS. Crude ORs and 95% 
CIs are also stratified by ethnicity to informally test for any evidence of effect 
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modification. Overall, the ADRB2 rsl042713 (Arg16Gly) polymorphism was not 
associated with breast cancer risk; the AI A genotype compared with the homozygous 
wild type genotype (GIG) was not statistically significant for the total sample or by ethnic 
group. When combined with the heterozygous GI A genotype and analyzed against the 
homozygous GIG genotype, results remained non-significant. As with rs 1 042713 
(Arg16Gly), the ADRB2 rs1042714 polymorphism was also not associated with breast 
cancer risk. Stratification by ethnicity did not reveal any significant results for the GIG 
genotype vs. the homozygous wild type (CIC) genotype or for the combination of the 
heterozygous C/G genotype and GIG genotype vs. the homozygous CIC wild type. The 
ADRB2 SNPs were not considered for further analyses due to their non-significant 
associations. 
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Table 7. Univariable Odds Ratios (OR) and 95% Confidence Intervals for Demographic Characteristics from the 4-Corners 
Breast Cancer Study 
Total Non-Hispanic White Hispanic 
(n=3,908) (n=2,S74} (n= 1,334) 
Variable/Covariates OR 95% CI P value OR 95% CI OR 95% CI 
Education 
High School or less Referent 1.00 Referent 1.00 Referent 1.00 
Some college 1.02 0.87-1.18 0.98 0.88 0.73-1.08 1.40 1.03-1.90 
Bachelor degree/higher 1.03 0.89-1.21 0.72 0.93 0.77-1.11 1.33 0.95-1.87 
Age at Menarche 
<12 Referent 1.00 Referent 1.00 Referent 1.00 
12 0.89 0.74-1.08 0.92 0.87 0.69-1.10 0.92 0.68-1.27 
13 0.88 0.73-1.06 0.90 0.92 0.73-1.16 0.77 0.55-1.06 
14+ 0.79 0.66-0.95 0.03 0.72 0.57-0.91 0.92 0.68-1.25 
Menopausal Status 
(Pre/Peri vs. Post) 1.15 1.01-1.32 0.03 1.17 1.00-1.37 1.16 0.93-1.44 
+:. Parity 
+:. Nulliparous Referent 1.00 Referent 1.00 Referent 1.00 
1-2 0.96 0.79-1.17 0.01 0.90 0.71-1.13 1.21 0.82-1.79 
3-4 0.80 0.66-0.98 0.40 0.78 0.62-0.99 0.94 0.63-1.38 
5+ 0.64 0.50-0.83 <0.01 0.57 0.41-0.79 0.86 0.55-1.34 
Family History (YIN) 1.58 1.34-1.87 <0.01 1.60 1.31-1.96 1.51 1.11-2.05 
Recent Exposure to HRT 
(YIN) 1.20 1.03-1.40 0.02 1.22 1.01-1.47 1.16 0.90-1.50 
Smoking Status 
Ever vs. Never 1.10 0.97-1.26 0.13 1.19 1.02-1.39 0.92 0.73-1.16 
Aspirin usage (YIN) 0.85 0.73-0.99 0.04 0.89 0.74-1.07 0.73 0.55-0.97 
NSAID usage (YIN) 0.96 0.82-1.09 0.44 1.02 0.86-1.20 0.79 0.62-1.01 
Table Cont 
Total Non-Hispanic White Hispanic 
(n=3,908) (n=2,574) {n= 1,334) 
Variable/Covariates OR 95% CI P value OR 95% CI OR 95% CI 
Waist Circumference (in). 
<77.7 Referent 1.00 Referent 1.00 Referent 1.00 
77.7-86.5 1.10 0.92-1.31 0.49 1.11 0.90-1.37 1.10 0.78-1.54 
86.6-97.7 1.09 0.91-1.29 0.64 1.19 0.96-1.47 0.96 0.68-1.34 
2:97.8 1.05 0.87-1.25 0.86 1.14 0.91-1.41 0.94 0.67-1.33 
BMI at ref. yr. (kg/m2) 
Normal Referent 1.00 Referent 1.00 Referent 1.00 
Overweight 0.95 0.82-1.10 0.64 1.02 0.85-1.22 0.84 0.65-1.10 
Obese 0.84 0.72-0.98 0.04 0.89 0.74-1.08 0.77 0.59-1.0 I 
Obese 
No (BMI < 30 kg/m2) Referent 1.00 Referent 1.00 Referent 1.00 
Yes (BMI 2: 30.0 kg/m2) 0.86 0.75-0.99 0.03 0.89 0.74-1.06 0.84 0.67-1.06 
+:>. WHR 
VI 
<0.8 Referent 1.00 Referent 1.00 Referent 1.00 
0.8 to 0.9 1.01 0.88-1.15 0.89 1.04 0.88-1.22 1.03 0.80-1.33 
>0.9 1.04 0.84-1.28 0.75 1.11 0.84-1.48 1.03 0.73-1.44 
History of Diabetes 
No Referent 1.00 Referent 1.00 Referent 1.00 
Borderline 0.98 0.73-1.1 0 0.40 0.86 0.64-1.14 0.97 0.72-1.31 
Yes 1.04 0.65-1.67 0.70 1.56 0.80-3.02 0.68 0.33-1.39 
Calories/day (Quartiles) 
Q.I (:S 1552.71) Referent 1.00 Referent 1.00 Referent 1.00 
Q.2 (1552.72-2067.34) 1.01 0.84-1.21 0.28 1.04 0.84-1.28 0.94 0.67-1.34 
Q.3 (2067.35-2814.58) 1.15 0.96-1.37 0.20 1.17 0.95-1.45 1.12 0.80-1.56 
Q.4 (2: 2814.59) 1.13 0.95-1.35 0.32 1.26 1.00-1.59 1.05 0.77-1.43 
Table Cont. 
Total Non-Hispanic White Hispanic 
(n=3,908) (n=2,S74} (n= 1,334} 
Variable/Covariates OR 95% CI P value OR 95% CI OR 95% CI 
Total Mets (Quartiles) 
Q.l « 250.00) Referent 1.00 Referent 1.00 Referent 1.00 
Q.2 (250.00-835.55) 0.94 0.77-1.11 0.40 0.87 0.70-1.10 0.99 0.75-1.33 
Q.3 (835.56-1848.78) 0.97 0.81-1.16 0.97 0.93 0.74-1.16 1.00 0.74-1.36 
QA (> 1848.78) 0.98 0.82-1.18 0.80 0.90 0.72-1.13 1.11 0.82-1.51 
Height (Quartiles) 
Q.l (:S 1.562) Referent 1.00 Referent 1.00 Referent 1.00 
Q.2 (1.563-1.610) 1.27 1.06-1.51 0.30 1.38 1.06-1.80 1.16 0.89-1.51 
Q.3 (1.611-1.656) 1.24 1.04-1.48 0.50 1.37 1.06-1.77 1.05 0.78-1.41 
. Q.4 (2: 1.657) 1.30 1.09-1.55 0.14 1.38 1.08-1. 76 1.24 0.84-1.83 
..j:o.. 
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Table 8. Univariable Odds Ratios (OR) and 95% Confidence Intervals for Genetic Polymorphisms from the 4-Corners Breast 
Cancer Study 
Total Non-Hispanic White Hispanic 
{n=3,908} {n=2,574} (n= 1,334} 
Variable/Covariates OR 95%CI P value OR 95% CI OR 95%CI 
ADRB2 (rslO42713) 
O-GIG Referent 1.00 Referent 1.00 Referent 1.00 
I-G/A 0.97 0.84-1.11 0.38 0.91 0.77-1.08 1.12 0.88-1.44 
2-A/A 1.05 0.87-1.27 0.47 1.05 0.82-1.34 1.13 0.82-1.54 
ADRB2 (rslO42714) 
O-C/C Referent 1.00 Referent 1.00 Referent 1.00 
I-G/C 0.98 0.86-1.13 0.93 1.00 0.83-1.19 0.89 0.70-1.12 
2-G/G 0.98 0.81-1.19 0.87 0.94 0.75-1.18 1.00 0.62-1.63 
ADRB2 (rslO42713) 
O-GIG Referent 1.00 Referent 1.00 Referent 1.00 
..j:::.. I-G/A or AlA 0.99 0.86-1.12 0.82 0.94 0.80-1.1 0 1.12 0.89-1.42 
-..J ADRB2 (rslO42714) 
O-C/C Referent 1.00 Referent 1.00 Referent 1.00 
I-G/C or GIG 0.98 0.83-1.12 0.77 0.98 0.83-1.16 0.90 0.72-1.13 
Haplotype A-G 
o copies Referent 1.00 Referent 1.00 Referent 1.00 
1 copy 0.94 0.81-1.08 0.28 0.89 0.75-1.05 1.08 0.85-1.38 
2 copies 1.02 0.85-1.23 0.56 1.02 0.80-1.30 1.09 0.80-1.49 
Continuous A-G 0.99 0.91-1.09 0.89 0.98 0.87-1.09 1.05 0.90-1.22 
Haplotype G-G 
o copies Referent 1.00 Referent 1.00 Referent 1.00 
1 copy 0.92 0.80-1.05 0.12 0.87 0.73-1.03 1.03 0.82-1.30 
2 copies 1.10 0.84-1.45 0.30 1.84 1.18-2.84 0.85 0.58-1.24 
Continuous G-G 0.98 0.88-1.09 0.67 1.02 0.89-1.17 0.96 0.82-1.13 
Table Cont. 
Total Non-Hispanic White Hispanic 
(n=3,90B} (n=2,S74} (n= 1,334} 
Variable/Covariates OR 95% cr P value OR 95% cr OR 95%CI 
Hap G-G Model 
"0 vs. 1+2" 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1+2 0.94 0.83-1.07 0.33 0.94 0.80-1.10 1.00 0.80-1.24 
Hap G-G Model 
"0+ 1 vs.2" 
0+1 Referent 1.00 Referent 1.00 Referent 1.00 
2 1.14 0.87-1.49 0.34 1.92 1.25-2.97 0.84 0.58-1.20 
Haplotype G-C 
o copies Referent 1.00 Referent 1.00 Referent 1.00 
1 copy 0.95 0.83-1.09 0.69 0.95 0.80-1.13 0.88 0.69-1.10 
2 copies 0.96 0.79-1.16 0.83 0.91 0.73-l.l4 1.00 0.61-1.62 
..j::.. 
Continuous G-C 0.97 0.89-1.06 0.52 0.95 0.86-1.06 0.93 0.78-l.l2 
00 ADRB3 (Arg64Trp) 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 0.98 0.83-1.16 0.34 0.90 0.72-l.l3 1.15 0.89-1.49 
2 1.32 0.75-2.34 0.33 1.20 0.46-3.11 1.52 0.74-3.12 
AR (AR_CAG repeat) 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 1.16 1.00-1.34 0.14 1.07 0.88-1.29 1.28 1.00-1.62 
2 1.11 0.93-1.32 0.68 1.03 0.83-1.28 l.l7 0.85-1.62 
ESRI Xba 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 0.98 0.86-1.12 0.65 1.02 0.86-1.20 0.90 0.72-l.l3 
2 1.03 0.84-1.27 0.71 1.00 0.78-1.29 1.08 0.73-1.60 
IGFI (19CA repeats) 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 1.07 0.94-1.23 0.85 1.06 0.90-1.25 1.10 0.87-1.39 
2 1.12 0.91-1.36 0.44 l.l7 0.91-1.50 1.05 0.73-1.47 
Table Cont. 
Total Non-Hispanic White Hispanic 
(n=3,908) (n=2,574) (n= 1,334} 
Variable/Covariates OR 95% CI P value OR 95% CI OR 95% CI 
IGFBP3 (202 C>A) 
0 Referent 1.00 Referent 1.00 Referent 1.00 
I 1.14 0.99-1.31 0.31 1.01 0.84-1.21 1.35 1.07-1.70 
2 1.13 0.94-1.36 0.48 1.05 0.84-1.31 1.16 0.82-1.66 
IRS-l (G972R) 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 1.06 0.87-1.29 0.80 0.98 0.78-1.24 1.25 0.86-1.82 
2 1.31 0.44-3.91 0.66 1.34 0.36-5.00 1.23 0.17-8.75 
IRS-2 (G 1057D) 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 0.98 0.85-1.12 0.41 1.00 0.85-1.19 0.93 0.74-1.19 
2 0.85 0.70-1.04 0.11 0.75 0.59-0.97 1.05 0.77-1.45 
+>-
SHBG (D327N) 
\.0 0 Referent 1.00 Referent 1.00 Referent 1.00 
1 1.13 0.96-1.33 0.76 1.13 0.93-1.36 1.09 0.80-1.48 
2 1.15 0.62-2.11 0.81 0.81 0.41-1.63 4.28 0.89-20.70 
VDR Bsml 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 1.14 1.00-1.31 0.20 1.10 0.93-1.31 1.17 0.93-1.47 
2 1.10 0.90-1.33 0.80 1.02 0.81-1.29 1.23 0.83-1.82 
VDR_PolyA tail 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 1.14 0.99-1.31 0.27 1.07 0.90-1.27 1.23 0.98-1.55 
2 1.11 0.91-1.35 0.67 1.08 0.86-1.36 1.06 0.72-1.56 
Table Cont. 
Total Non-Hispanic White Hispanic 
{n=3,908) {n=2,574) (n= 1,334) 
Variable/Covariates OR 95% CI P value OR 95% CI OR 95% CI 
IL6 (rs1800797) 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 0.86 0.75-0.98 0.30 0.81 0.69-0.97 0.80 0.63-1.02 
2 0.85 0.70-1.04 0.38 0.72 0.58-0.91 1.49 0.85-2.60 
IL6 ( rs1800796) 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 1.02 0.87-1.20 0.92 1.30 1.02-1.66 0.90 0.72-1.14 
2 1.02 0.69-1.50 0.97 1.66 0.47-5.90 1.00 0.66-1.53 
IL6 (rs1800795) 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 0.83 0.73-0.95 0.14 0.78 0.65-0.92 0.82 0.64-1.03 
2 0.86 0.70-1.04 0.50 0.74 0.59-0.92 1.27 0.74-2.16 
VI IL6( rs2069832) 
0 0 Referent 1.00 Referent 1.00 Referent 1.00 
I 0.84 0.74-0.97 0.23 0.79 0.66-0.94 0.82 0.64-1.03 
2 0.85 0.69-1.03 0.37 0.72 0.58-0.91 1.27 0.75-2.15 
IL6 (rs2069849) 
0 Referent 1.00 Referent 1.00 Referent 1.00 
1 0.90 0.71-1.16 0.50 1.04 0.71-1.51 0.85 1.19 
2 0.37 0.04-3.55 0.41 1.07 0.07-17.19 <0.001 >999.999 
Definitions ojSNP categories: "O"=homozygous wild type, "1 "=heterozygote, "2"= homozygous variant 
Abbreviations: ADRB2- Adrenergic Receptor Beta-2, HAP-haplotype, ADRB3- Adrenergic Receptor Beta-3, AR- Androgen 
Receptor, ESRI-Estrogen Receptor Alpha, IGFI- Insulin Growth Factor-I, IGFBP3- Insulin Growth Factor Binding Protein-3, IRS-I-
Insulin Receptor Substrate-I, IRS-2- Insulin Receptor Substrate-2, SHBG- Sex Hormone Binding Globulin, VDR- Vitamin D 
Receptor, IL6- Interleukin 6. 
Among the entire sample, none of the three ADRB2 haplotypes were associated 
with breast cancer risk; however the G-G haplotype did have a significant crude 
association among NHW women with 2 copies of the haplotype compared to zero copies, 
producing an OR= 1.84, 95% CI: 1.18-2.84 (Table 8). In contrast, Hispanic women did 
have a non-significant inverse association for the G-G haplotype, with an OR=0.85, 95% 
CI: 0.58-1.24 (Table 8). Because the significant association with NHW was observed, it 
was of interest to assess the G-G haplotype association with the dominant and recessive 
model of inheritance. The dominant model "0 vs. 1 +2" was not found to be significantly 
associated with breast cancer for the total sample or by ethnic group. The recessive model 
of "0+ 1 vs. 2", however, did yield a stronger crude association with breast cancer risk 
among NHW women (OR= 1.92,95% CI: 1.25-2.97) (Table 8). The magnitude of the 
association did not significantly change for Hispanics. Modeling the G-G haplotype as a 
continuous variable did not provide significant results for this study and was not 
considered further for analyses. The following polymorphisms from Table 8 were 
identified and considered for interaction effects with the G-G haplotype due to their 
function and potential associations with risk of diabetes and/or obesity: IRS-I, IRS2, 
ADRB3, IGF-1, and IL6 variants. 
Effect modification by ethnicity for the association with the G-G haplotype and 
risk of breast cancer was formally tested by using an interaction term in a multivariable 
logistic regression model consisting of the G-G haplotype, the ethnicity variable, and the 
interaction term between the G-G haplotype and ethnicity variable. The interaction 
between ethnicity and the G-G haplotype was statistically significant with a p value of 
0.004 (Table 9). 
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Table 9. Test ofInteraction with Ethnicity using Model "0+1 vs. 2" G-G Haplotype 
for ADRB2 
Variable Estimate Standard Error p- value 
G-G Haplotype 
Ethnicity 










An ethnic-specific haplotype variable was constructed to further examine the 
relationship between the G-G haplotype and breast cancer risk by ethnicity. The referent 
group consisted ofNHW women with 0 copies of the G-G haplotype. Multivariable 
logistic regression models were evaluated using the ethnic-specific haplotype variable 
and the significant predictors from Table 7. Overall, none of the significant confounders 
from the univariable analysis significantly changed the point estimate; however, the final 
model was concluded based on the a priori knowledge of the relationship between the 
ADRB2 haplotype with breast cancer risk. After adjusting for center, BMI at referent 
year, menopausal status, history of diabetes, and genetic admixture, there was a positive 
association between the G-G haplotype with the recessive model and breast cancer risk 
among NHW women. Although the inverse association observed for Hispanic women 
was not statistically significant by itself, the heterogeneity test for difference between 
ethnic groups was significant (p=0.004) (Table 10). 
Table 10. Interaction between Ethnicity and G-G Haplotype of ADRB2 SNPs Using 
Model "0+ 1 vs. 2" a 
Haplotype Levels of 
G-G 














a Odds ratios and 95% Confidence Intervals adjusted for center, 8MI at referent yr (one year prior to 
date of diagnosis for cases and one year prior to selection for controls), menopausal status, history of 
diabetes, and genetic admixture. 
h P value for heterogeneity test difference between NHW and Hispanic women 
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Table 11. Test of Effect Modification by History of Diabetes with Ethnic-Specific 
ADRB2 G-G Haplotype. 
History of Diabetes 
o copies of G-G Haplotype 
1 copy of G-G Haplotype 
2 copies of G-G Haplotype 





















o copies ofG-G Haplotype Referent 1.00 0.79 0.61-1.02 
1 copy ofG-G Haplotype 0.85 0.71-1.02 0.86 0.66-1.12 
2 copies ofG-G Haplotype 1.77 1.13-2.77 0.86 0.55-1.33 
Odds ratios and 95% Confidence Intervals adjusted for center, BMI at referent yr (one 
year prior to date of diagnosis for cases and one year prior to selection for controls), 
menopausal status, and genetic admixture. 
Effect modification by history of diabetes was tested with the association between 
the G-G haplotype and breast cancer. The divergence among ethnicities for the 
association with breast cancer risk was greater when modeled by history of diabetes. In 
fact, a significant inverse association was observed among Hispanics with 2 copies of the 
G-G haplotype (OR=0.33; 95%:0.12-0.92) compared to NHW who yielded a non-
significant positive association of 4.91,95% CI: 0.52-46.60 (Table 11). The 
multiplicative two-way interaction with history of diabetes was also significant when 
modeled as an interaction term with the G-G haplotype (p= 0.025). The three-way 
multiplicative interaction term between the ethnic-specific haplotype and diabetes yielded 
a non-signification effect (p for interaction= 0.137). 
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Table 12. Test of Effect Modification by Obesity with Ethnic-Specific ADRB2 G-G 
Haplotype 
BMI< 30 kg/m2 
o copies of G-G Haplotype Referent 1.00 0.82 0.62-1.09 
1 copy of G-G Haplotype 0.83 0.68-1.00 0.83 0.61-1.11 
2 copies ofG-G Haplotype 1.58 0.95-2.61 0.95 0.59-1.54 
Odds ratios and 95% Confidence Intervals adjusted for center, history of diabetes, 
menopausal status, and genetic admixture. 
Effect modification by obesity status (BMI ~ 30 kg/m2 VS. BMI <30 kg/m2) was 
also examined with the association between the G-G haplotype and breast cancer. The 
divergence among ethnicities for the association with breast cancer risk was also 
enhanced when modeled by obesity and significant results were found for both ethnic 
groups. Among the obese group with 2 copies of the G-G haplotype, NHW women had 
an increased risk of breast cancer with an OR= 3.01 (95% CI: 1.22-7.44) while Hispanics 
had a reduced risk with an OR=0.42 (95% CI: 0.20-0.86). Associations were not 
significant among women with BMI < 30 kg/m2 (Table 12). Interestingly, the two-way 
multiplicative interaction effect between obesity and the G-G haplotype was not 
statistically significant (p=0.200), neither was the three-way interaction with the ethnic-
specific haplotype and obesity variable (p= 0.155). 
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Table 13. Test of Effect Modification by Recent Hormone Exposure with Ethnic-
Specific ADRB2 G-G Haplotype 
Non-Hispanic White Hispanic 
(n=2,574) (n=1,334) 
OR 95% CI OR 95% CI 
No Recent Hormone EXEosure 
o copies of G-G Haplotype Referent 1.00 1.08 0.65-1.79 
1 copy of G-G Haplotype 1.11 0.77-1.60 1.10 0.66-1.83 
2 copies of G-G Haplotype 4.58 1.34-12.82 0.58 0.24-1.40 
Recent Hormone EXEosure 
o copies of G-G Haplotype Referent 1.00 0.78 0.59-1.02 
1 copy ofG-G Haplotype 0.83 0.68-1.00 0.81 0.61-1.07 
2 copies ofG-G Haplotype 1.47 0.90-2.41 0.76 0.49-1.18 
Odds ratios and 95% Confidence Intervals adjusted for center, BMI at referent yr (one 
year prior to date of diagnosis for cases and one year prior to selection for controls), 
menopausal status, history of diabetes, and genetic admixture. 
Results for effect modification by recent hormone exposure within the past 2 
years were only significant among NHW women with no recent hormone exposure. 
Hispanic women with no recent hormone exposure did have a reduced risk of breast 
cancer with 2 copies of the G-G haplotype, however, the confidence interval was not 
significant and when compared to the recent hormone exposure group, point estimates for 
Hispanic women were not dramatically different. Among NHW, no recent hormone 
exposure did significantly increase the risk of breast cancer with women who had 2 
copies of the G-G haplotype, but the confidence interval was wide, due to the fact that 
only a small subset of women were included among this risk group (n=22 subjects) 
(OR=4.58; 95% CI: 1.34-12.82) (Table 13). 
As hypothesized, it was of interest to investigate interaction effects between the 
ADRB2 G-G haplotype and family history of breast cancer (p for interaction =0.686), 
menopausal status (p for interaction =0.438), aspirin use (p for interaction= 0.983), and 
the identified insulin-related polymorphisms previously studied with the 4-CBCS (IRS-I, 
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IRS-2, ADRB3, IGF-l, and IL6 variants). There were no significant interactions between 
the G-G haplotype and ethnicity with polymorphisms for IRS-I, IRS-2, ADRB3, IGF-l, 
and IL6 variants (Table 14). Adjusting for the specified SNPs of interests in the model 
did not significantly change the value of the point estimate for the ethnic-specific 
haplotype variable as well (data not shown). 
Table 14. Statistical Interactions between ADRB2 G-G Haplotype by Ethnicity 
Interaction Variable Non-Hispanic White Hispanic 
with G-G Haplotype P for interaction P for interaction 
ADRB3 (Arg64Trp) 0.968 0.725 
IRS-l (G972R) 0.541 0.989 
IRS-2 (G 1 057D) 0.329 0.306 
IGF-l (l9CA repeats) 0.964 0.827 
IL6 (rsI800797) 0.588 0.358 
IL6 (rs1800796) 0.961 0.780 
IL6 (rs 1800795) 0.492 0.118 
IL6 (rs2069832) 0.265 0.239 
Abbreviations: ADRB3- Adrenergic Receptor Beta-3, IRS-l- Insulin Receptor Substrate-
1, IRS-2- Insulin Receptor Substrate-2, IGF-l- Insulin Growth Factor -1, 
IL6- Interleukin 6. 
(IL6 rs2069849- validity of interaction with logistic regression models were questionable 
due to small numbers) 
It was also of interest to evaluate the ADRB2 genetic association with estrogen 
receptor status. The distribution of the estrogen receptor status among the breast cancer 
cases is found in Table 15. More Hispanic cases had estrogen receptor negative (ER-) 
tumors compared to NHW cases, and the difference between ethnicities was statistically 
significant (p= 0.04). 
56 
Table 15. Distribution of Estrogen Receptor (ER) Status for Breast Cancer Cases 
from the 4-Corners Breast Cancer Study 
Hispanics Non-Hispanic P value 
(n= 606) White (n=1,244) 
ER Status N (%) N (%) 
Positive 285 (47.0) 638 (51.3) 0.04a 
Negative 99 (16.3) 164 (13.2) 
Unknown 112 (18.5) 232 (18.6) 0.50b 
a P-value, Mantel-Haenszel Chi-Square, calculated without "Unknown" category. 
b P-value, Mantel-Haenszel Chi-Square, including "Unknown" category. 
In order to test the outcome of estrogen receptor status, multinomial logistic 
regression models were used with the ethnic-specific G-G haplotype to compare risk 
groups. Point estimates were comparable and not significant among Hispanic women 
with 2 copies of the G-G haplotype for ER positive and ER negative tumors. However, 
NHW women with 2 copies of the G-G haplotype did have a slightly higher risk for ER 
negative tumors compared to ER positive tumors, (OR=2.22; 95% CI: 1.03-4.78 and 
OR=1.71; 95%:1.02-2.88 respectively) (Table 16). 
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Table 16. Multinomial Logistic Regression by Estrogen Receptor Status with 
Ethnic-Specific ADRB2 G-G Haplotype 
Non-Hispanic White Hispanic 
(n=2,574) (n=I,334) 
OR 95%CI OR 95%CI 
Estrogen ReceEtor Positive 
o copies of G-G Haplotype Referent 1.00 0.73 0.57-0.93 
1 copy of G-G Haplotype 0.82 0.67-1.01 0.89 0.71-1.12 
2 copies of G-G Haplotype 1.71 1.02-2.88 0.65 0.40-1.03 
Estrogen ReceEtor Negative 
o copies ofG-G Haplotype Referent 1.00 1.18 0.82-1.70 
1 copy ofG-G Haplotype 0.90 0.63-1.28 1.04 0.71-1.53 
2 copies of G-G Haplotype 2.22 1.03-4.78 0.60 0.25-1.42 
Odds ratios (ORs) and 95% Confidence Intervals (95% CI) adjusted for center, BMI at 
referent yr (one year prior to date of diagnosis for cases and one year prior to selection 
for controls), menopausal status, history of diabetes, and genetic admixture. 
For this dissertation, it was also hypothesized to test the association of the 
ADRB2 polymorphisms and haplotypes with risk of obesity and diabetes. Unadjusted 
logistic regression models were constructed with the ethnic-specific G-G haplotype to 
investigate the association with both obesity at referent year, measured as BMI ~ 30 
kg/m2 vs. BMI<30 kg/m2, and history of diabetes. Table 17 displays the results for the 
association of the G-G haplotype by ethnicity with risk of Type 2 diabetes and borderline 
disease. Hispanic women did have a positive association for Type 2 diabetes, regardless 
of the number of haplotype copies, suggesting that there is no association between the 
haplotype with diabetes. Results from Table 18 for the association with obesity by 
haplotype level and ethnicity look somewhat similar to results for history of Type 2 
diabetes. It could be possible that the effect observed in these two tables by ethnicity is 
entirely due to ethnicity. This further suggests that there is something else associated 
with obesity and ethnicity and it could possibly be modifying the effect of the haplotype 
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on breast cancer risk. No interaction effects existed between the haplotype and the other 
related SNPs (Table 14) which implies that it is not any of the other obesitylinsulin 
related SNPs from the parent study. Therefore, this factor that is potentially associated 
with obesity, ethnicity, and breast cancer risk remains to be determined. 
Table 17. Association between Ethnic-Specific G-G Haplotype of ADRB2 SNPs with 
Diabetes/Borderline Diabetic. 
Non-Hispanic White Hispanic 
Haplotype Levels ofG-G (n=2,574) (n=1,334) 
OR (95% CI) OR (95% CI) 
o (referent) 1.00 (Referent) 1.97 (1.52-2.57) 
1 copy 0.83 (0.62-1.11) 1.69 (1.28-2.21) 
2 copies 0.52 (0.21-1.30) 2.56 (1.66-3.96) 
Unadjusted Odds ratios (ORs) and 95% Confidence Intervals (95%CI). 
Table 18. Association between Ethnic-Specific G-G Haplotype of ADRB2 SNPs with 
Obesity (BMI :::: 30). 
Non-Hispanic White Hispanic 
Haplotype Levels of G-G (n=2,574) (n=1,334) 
OR (95% CI) OR (95% CI) 
o (referent) 1.00 (Referent) 1.59 (1.30-1.94) 
1 copy 0.92 (0.76-1.12) 1.44 (1.17-1.76) 
2 copies 1.05 (0.65-1.70) 1.84 (1.28-2.65) 
Unadjusted Odds ratios (ORs) and 95% Confidence Intervals (95%CI). 
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DISCUSSION 
For this dissertation, the primary aim was to analyze the hypothesized association 
between the ADRB2 SNPs (rsl042713 (Arg16Gly); rsl042714 (Gln27Glu) and breast 
cancer risk, with particular concern on testing for effect modification by ethnicity. Within 
this sample of women, it was found that the candidate SNPs individually were not 
significantly associated with breast cancer risk, even after stratifying by ethnicity. Three 
haplotypes were identified between these two polymorphisms and were assessed with 
breast cancer risk as well, but a significant association was only observed for the G-G 
haplotype among non-Hispanic white women. Haplotypes for these two variants have 
proven to be worth researching. 
The study of haplotypes renders certain concepts that should be discussed. Clark 
presented in his review that genetic variation within populations is organized into 
haplotypes, and using haplotypes versus the "one-SNP-at a time" approach for genetic-
association studies could improve analyses by reducing the dimension of association 
tests, which could in turn increase statistical power [56]. Association studies could be 
performed without taking into account that the SNPs are not independent of one another; 
however the linkage disequilibrium between the SNPs should be considered with the 
biological interpretation [56]. Clark emphasizes the importance ofhaplotypes, as they are 
biologically relevant with genetics. With each protein coding gene, an individual will 
have a polypeptide chain that corresponds with the maternal haplotype and one for the 
paternal haplotype. The biological importance of haplotypes results from the interactions 
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that may occur between pairs or higher-order combinations of amino-acid sites [56]. The 
frequency of a haplotype encoding a new mutation may rise due to genetic drift. The 
haplotype could then become segmented due to recombination, and transmitted as a unit. 
Genetic variation then results not only from the recombination, but also from a 
combination ofmigrationlpopulation mixing, drift, selection, and mutation [56]. It is the 
genetic variation that is of interest when assessing any potential causal associations with 
disease risk. 
Cagliani et al. [57] concluded that the structure of the ADRB2 haplotypes could 
warrant the need for association studies. It was also indicated that these association 
studies would benefit from identifying an ethnic-specific haplotype and this 
recommendation is based on the fact that their analysis revealed ethnic-specific 
differences among five human populations from the National Institute of Environmental 
Health Sciences (NIEHS) SNPs Program [57]. Cagliani et al. also notes that the 
complexity of the ADRB2 inferred haplotypes could be attributed to one of two 
situations: the gene has been subjected to balancing selection or it has been undergoing a 
selective sweep. In a report by Hernandez at al. [58], researchers identified the "classic 
selective sweep" model. This model occurs when the frequency increases for a new, 
strongly favorable mutation in a fixed population. The allele rises so swiftly in frequency 
there is little time for recombination and for it to uncouple itself from its genetic 
background. This process is further characterized by the allele sweeping out variation at 
linked sites, which in turn lowers the linked neutral diversity within the population and 
distorts the allele frequencies and linkage disequilibrium patterns [58]. 
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The study by Cagliani et al. also documented ADRB2 genotype differences across 
population samples for genotypes with maximum and minimum relative fitness [57]. 
Theoretical models have shown that complex genotype distributions and differences 
among genotype frequencies could be caused by epistasis [59] and maternal selection 
[60], and Cagliani et al. believe both situations could potentially explain the ADRB2 
genotype differences. Cagliani et al. also identified variation within the promoter region 
of the ADRB2 polymorphisms. For Europeans, all chromosomes carrying the Arg16 ('A' 
allele for rs1042713) and Gln27 ('C' allele for rs1042714) alleles display the same 
promoter structure; but in all other populations, the haplotypes' coding variants are split 
into two groups, and have different alleles in their promoter regions, suggesting different 
transcriptional activity [57]. This difference in transcriptional activity could possibly 
influence the ethnic differences observed among the G-G haplotype within this 
dissertation study. 
In a report published prior to the review conducted by Cagliani and colleagues, 
Maxwell et al. investigated the ADRB2 haplotypes in eight distinct ethnic populations 
(Chinese, Southwest Asian, Saudi, Ghanaian, Kenyan, Sudanese, European, and 
Filipino). Haplotypes were shared among all ethnic groups, however, geographical 
variations were found in the frequency of the haplotype distributions. Maxwell et al. 
believe the ADRB2 haplotypes may have experienced a different mode of evolution for 
that locus compared to that of the human popUlation gene-flow history [61]. It was also 
proposed that the differences among the frequencies between the observed clusters of 
populations resemble the historical haplotype groupings that have been found to have 
differences in functionality in regards to multiple disease related phenotypes [61]. 
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As previously mentioned, the three ADRB2 haplotypes identified were, as 
follows: A-G (ArgI6-Glu27), G-G (GlyI6-Glu27), and G-C (GlyI6-Gln27). 
Interestingly, recent literature indicates for the common ADRB2 SNPs rsl042713 
(ArgI6Gly) and rsl042714 (Gln27Glu), that linkage disequilibrium dictates that Glu27 
homozygotes ofrsl042713 are nearly always homozygous for Gly16 ofrsl042714, and 
Arg16 homozygotes ofrs 1 042713 are homozygous for Gln27 of rsl 042714 [17,62-63]. 
The G-G haplotype which codes for Gly16-Glu27 was significantly associated with 
breast cancer in this dissertation study; and these results were only apparent in ethnic-
specific analyses. Thus, ethnicity was found to be a significant effect modifier, yielding a 
statistically significant interaction effect with the G-G haplotype (p=0.004). 
This is the first population-based case-control study to identify an association 
with an ADRB2 haplotype and breast cancer risk, although the effect differs between 
Hispanic and non-Hispanic white women. Two previous studies of individual ADRB2 
SNPs reported either null [16] or inverse associations [15]; however, neither report 
investigated the association of ADRB2 haplotypes within the two most common ADRB2 
variants and risk of breast cancer. Prior et al. [64] examined the relationship between 
ADRB2 haplotypes and glucose tolerance among a small sample of sedentary African 
American and non-Hispanic white women from Baltimore, Maryland. A specific aim of 
these researchers was to study the ADRB2 variants in the context of one haplotype, in an 
effort to address the inconsistencies from findings of previous studies that only looked at 
the individual genotypes for rsl042713 (ArgI6Gly) and rsl042714 (Gln27Glu). Prior et 
al. concluded that ADRB2 haplotypes may mediate insulin action and possibly the risk of 
Type 2 diabetes in obese, postmenopausal women [64]. 
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Unlike the previous studies with ADRB2 and breast cancer risk, this study was 
also able to test for interaction effects with Type 2 diabetes, given the relationship 
between the ADRB2 haplotypes with risk of Type 2 diabetes. As previously described, 
non-Hispanic white women with a history of diabetes and with 2 copies of the G-G 
haplotype had an increased risk of breast cancer, although the association was not 
statistically significant. In contrast, among Hispanic women, a statistically significant 
inverse association was observed. Results were not comparable for the non-diabetic 
group. One could infer diabetes is operating as an effect modifier in this breast cancer 
relationship, as it appears to enhance the divergent effect between Hispanic and non-
Hispanic whites. 
The relationship between diabetes and breast cancer has been extensively studied, 
and findings have been inconsistent. Rollison et al. [65] investigated the association 
within the 4-CBCS in a previous publication. It was concluded that, overall, diabetes was 
not associated with breast cancer risk, even after stratification by ethnicity. In a 
systematic review of breast cancer associations with adiposity, Type 2 diabetes, and the 
metabolic syndrome, Vona-Davis et al. [66] identified ten epidemiological studies that 
reported diabetes to be a significant risk factor for breast cancer and two studies that did 
not find diabetes to a significant predictor. The report further evaluated several biological 
mechanisms by which the metabolic syndrome, central obesity, and Type 2 diabetes 
mutually promote the risk of breast cancer; however these mechanisms may occur 
differently among some populations. Vona-Davis and colleagues propose that the 
extraglandular oestrogen production and subsequent reduction in sex hormone-binding 
globulin increase the risk for hyperinsulinemia, resulting in increased plasma free 
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oestradiol. This hormone driven cycle has mitogenic effects and triggers mitosis in breast 
epithelial cells. Increased leptin and decreased adiponectin production have also been 
implicated with breast cancer risk [66]. In a review on diabetes and breast cancer, Wolf 
et al. proposed three possible mechanisms responsible for the association between 
diabetes and breast cancer: activation of the insulin pathway, the regulation of 
endogenous sex hormones, and the activation of the insulin-like growth factor pathway 
[67]. In a later case-control study consisting of 79 diabetic and 158 age-matched non-
diabetic patients, Wolf et al. reported that the relationship between diabetes and breast 
cancer remained even after adjustment for BMI [68]. 
The causal pathway between the ADRB2 G-G haplotype and breast cancer is 
difficult to explain. As previously discussed, the ADRB2 rsl042713 (ArgI6Gly) and 
rs1042714 (Gln27Glu) have been found to be associated with proven risk factors for 
breast cancer, i.e. diabetes and obesity. However, for this study diabetes appears to 
strengthen the interaction effect of the ADRB2 G-G haplotype and ethnicity. One would 
suspect obesity to playa similar role with this association. As previously reported, when 
tested as an interaction term in the logistic regression model with the G-G haplotype and 
obesity measured as BMI 2: 30 kg/m2, the interaction was not statistically significant (p-
value= 0.200). Yet, when the interaction between G-G haplotype and ethnicity was 
stratified by obesity status and adjusted for other important covariates, divergent results 
emerged. Among non-Hispanic white women with 2 copies of the G-G haplotype who 
were obese, the odds ratio was not only magnified but was also statistically significant. 
Conversely, a significant reduction for breast cancer risk was also observed for obese 
Hispanic women with 2 copies of the G-G haplotype. For women who are not obese, 
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categorized by BMI <30 kg/m2, the results were not significant by ethnicity, and the 
divergence was weakened. Furthermore, when assessed as a single confounder and 
adjusted for in analyses, BMI was not found to be a significant covariate. 
The biological relationship between ADRB2 and obesity has been widely studied, 
and results have been found to differ between the two common SNPs. The rsl042714 
SNP was found to be strongly associated with obesity in women [9]. Arner et al. [18] 
hypothesized that this particular ADRB2 variant is a potentially important gene 
polymorphism for obesity research as it could be considered a 'thrifty' gene as with the 
other adrenergic receptor genes [69]. Developed by James Neel, the "thrifty genotype" 
hypothesis described a hypothetical set of alleles that many diabetics are thought to carry 
in a small number of genes that would make them more effective with the intake and 
utilization of food. The theory was first thought to be related with Type 2 diabetes; 
however, since obesity often precedes diabetes, the theory could also be applied to 
obesity [70]. During times of "feast-or-famine" and when civilizations depended upon 
hunting and gathering, this genotype benefited humans [70]. However, among 
westernized society, this genotype is problematic, as it has been thought to increase the 
ability to store and reserve extra pounds, leading to obesity and risk of Type 2 diabetes. 
In a more recent report, Eisenach et al. suggested that the ADRB2 rsl042714-
Gln27, also known as the 'C' allele, may actually play an intermediate role in the 
development of obesity, as this specific allele has been linked with lower rate of lipolysis 
[17]. Lange et al. also found an association between rsl042714 and adipose tissue 
deposition [71]. Their findings have implications for risk of insulin resistance and 
diabetes. Visceral adipose tissue plays an important role in the development of these 
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conditions. The vasculature of visceral adipose tissue allows free fatty acid flux into the 
liver, which leads to suppression of hepatic glucose production, hyperinsulinemia, and 
increased secretion of triglyceride particles [71]. The visceral cells have high lipolysis 
rates because of the elevated function of the beta-adrenergic receptors and decreased 
function of anti lipolytic receptors. Visceral adipocytes also express lower levels of 
protective proteins against diabetes, i.e. adiponectin, leptin, and glycogen synthase [71]. 
The ADRB2 rs1042713 has also been implicated with risk of obesity as it has 
been found within adipose cells. 10cken et al. found that ADRB2 actually mediates 
lipolysis; they reported that obese women with homozygous Arg16 (homozygous AlA) 
genotypes had a marked increase in circulating free fatty acids and glycerol, and 
decreased fat oxidation [72]. From these results, it appears that the relationship between 
the two ADRB2 SNPs and obesity is not consistent between genotypes for each SNP. 
More research is needed to investigate any haplotype involvement between the ADRB2 
gene and obesity. Within this study, the G-G haplotype did increase the risk of obesity; 
but interestingly, this positive association was only observed among Hispanics. Although 
the mUltiplicative interaction between obesity and the G-G haplotype was not significant 
for breast cancer, some evidence of effect modification was present. The complexity of 
the divergence between the point estimates by ethnicity still remains and is a chief theme 
of interest. 
As noted earlier, ADRB2 haplotypes have been reported to be associated with 
insulin resistance and, more specifically, have been posited to mediate insulin action and 
the risk for Type 2 diabetes in obese women [64]. Results from this dissertation show the 
positive association between the G-G haplotype and risk of Type 2 diabetes was only 
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significant among Hispanic women. The association between insulin and estrogen 
receptor status has been investigated for diabetes and breast cancer [66, 68, 73], but not 
for the ADRB2 gene or haplotypes. In vitro insulin has a mitogenic effect, stimulating 
mitosis within ER-positive breast cancer cell lines. Insulin also increases aromatase 
activity, which also elevates mitogenic oestrogen levels [66]. Michel et al. concluded in 
the Nurses' Health Study that the relationship between Type 2 diabetes and breast cancer 
occurred mainly with ER-positive tumors [73]. In contrast, Wolf et al. [68] found breast 
cancer among diabetic patients was more strongly associated with estrogen receptor 
negative breast cancer. More research between diabetes and breast cancer ER status is 
warranted. 
It was also of interest for this dissertation to evaluate the relationship between 
ADRB2 and estrogen receptor positive and negative breast cancer. This relationship was 
also attractive due to the established connection between ADRB2 and risk of Type 2 
diabetes and because of the conflicting findings with the association between diabetes 
and ER status. Multinomial logistic regression was conducted to examine the association 
between the ADRB2 G-G haplotype and ethnicity by ER status. There were significant 
results for non-Hispanic white women with ER positive breast cancer; however the 
association was only marginally higher for ER negative tumors. Interestingly, for this 
population of women, more Hispanic women had ER negative tumors compared to non-
Hispanic white, yet non-significant inverse associations were present for both categories 
of ER status. Overall, these findings for this relationship did not indicate significant 
differences in breast cancer risk by estrogen receptor status. 
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It was hypothesized that there would be significant interaction effects between the 
ADRB2 haplotype and the ADRB3 polymorphism, Trp64Arg, due to their functional 
relatedness in Type 2 diabetes and obesity research; however, a significant interaction 
was not indicated with these results. To date, there are no breast cancer epidemiological 
studies that have investigated interaction effects between ADRB2 haplotypes and the 
ADRB3, Trp64Arg. In fact, few publications have investigated the potential for 
interaction effects between the ADRB2 and ADRB3 polymorphisms with risk of obesity 
[74-76] and diabetes [77], and mixed results have been reported. Park and colleagues 
examined the interaction between ADRB2 and ADRB3 polymorphisms with adolescent 
obesity and observed a significant interaction effect between ADRB2 variant rs1042714 
and Trp64Arg on BMI (p<O.01) [75]. In the study conducted by Ellsworth et aI., 
significant interactions on change in BMI were only found between polymorphisms for 
beta-1 and beta-3 receptors among women from this cohort, and no significant effects 
were reported between ADRB2 and ADRB3 variants. It would be of interest for future 
genetic association studies to evaluate this potential interaction among other populations, 
not only for breast cancer risk, but also for obesity and diabetes research. 
Previous publications for the 4-CBCS have documented marked ethnic 
differences in genetic associations with breast cancer risk [27, 31, 78]. Slattery et al. 
examined the relationship between IRS-1, IRS-2, and IGFBP3 and breast cancer risk with 
the 4-CBCS [27]. Ethnic differences were found between Hispanic and non-Hispanic 
white women who were not recently exposed to hormones and post-menopausal. Among 
post-menopausal Hispanic women not recently exposed to hormones, an increased risk of 
breast cancer was observed with the R allele of the G972R IRS 1 polymorphism. This 
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effect was not observed among non-Hispanic white women. Conversely, post-
menopausal non-Hispanic white women not recently exposed to hormones showed an 
increased risk of breast cancer with the IGF-1 19 CA polymorphism; while there was no 
association in the Hispanic group. These findings further support the roles of the insulin 
and estrogen pathways in breast cancer risk, and also indicate how these metabolic 
pathways that potentially influence breast cancer may differ between ethnic groups [27]. 
In light of these findings with IRS-l and IGF-1 polymorphisms, it was of interest 
to test if recent hormone exposure also modified the effect between ethnicity and the 
ADRB2 G-G haplotype. Interestingly, non-Hispanic white women with the highest level 
of the G-G haplotype, who had no recent hormone exposure within the past 2 years, were 
at significantly increased risk. For non-Hispanic white women who were exposed to 
HR T within the past 2 years and who had the highest level of the G-G haplotype, the risk 
was sharply attenuated and not significant. In contrast, recent hormone exposure did not 
significantly alter the risk estimates in Hispanic women, similar to results for the IGF-1 
19 CA polymorphism [27]. 
In another report, Slattery et al. [31] investigated the association of the Xb 1 
polymorphism of estrogen receptor alpha (ESR1) and the CAG repeat of the androgen 
receptor (AR) genes with risk of breast cancer. Independently, the two polymorphisms 
did not have a significant association with breast cancer for Hispanic or non-Hispanic 
white women; however a statistically significant inverse association was observed for 
Hispanic women taking hormone therapy with the X allele (OR = 0.61; 95% CI: 0.39-
0.94). In contrast, there was no statistically significant association among non-Hispanic 
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white women. These findings further suggest that certain risk factors, such as effects of 
estrogen signaling, may differ for Hispanic and non-Hispanic White women [31]. 
It remains unclear why the ethnic differences between Hispanic and non-Hispanic 
white women occur in the realm of breast cancer research. Researchers attempt to adjust 
for potential confounding effects by including other covariates in analyses; however in 
the present research study adjusting for these covariates does not significantly affect the 
divergence in the associations. Lai et al. [79] posed a few intriguing concepts in an effort 
to explain the underlying circumstances behind these ethnic differences. Could subjects 
in the two ethnic groups be exposed to different environmental mutagens or to 
endogenous factors? Or could it be possible that the host reactions to breast cancer 
carcinogens differ between ethnicities? Or lastly, are there still unidentified oncogenes 
and/or tumor suppressor genes involved? [79]. 
Another intriguing concept within this dissertation study is how the ADRB2 G-G 
haplotype increased the risk of Type 2 diabetes and obesity in Hispanic women, but 
decreased the risk of breast cancer. Among non-Hispanic white women, the reverse 
effects were observed. It could be possible for the G-G haplotype that causes these 
amino-acid changes to cause a shift in the biochemistry of breast cancer carcinogenesis. 
Could the undetermined environmental mutagens posed by Lai et al. influence this shift? 
Or it could be the interaction of environmental factors with genetic background that is 
causing this divergence in association between these two ethnicities. 
There are several strengths to this dissertation study. This study utilized 
population-based cases and controls to investigate the association between the two most 
common ADRB2 polymorphisms and their haplotypes and breast cancer risk. As 
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previously mentioned, only two previous studies have examined the association between 
the ADRB2 gene and breast cancer risk: Huang et al. [15] investigated the association 
with only the rsl042714 (Gln27Glu) ADRB2 variant, while Feigelson et al. [16] utilized 
four ADRB2 tagging SNPs to assess the association with breast cancer. Neither of the 
studies included both of the common ADRB2 variants nor performed haplotype analyses. 
This is also the first study to report a significant positive association between an ADRB2 
haplotype and breast cancer risk among non-Hispanic white women from a multi-
centered study in the United States. 
There are common limitations with the genetic-association study design that 
should be addressed. The most common limitation among genetic-association studies can 
be attributed to the use of small sample sizes, which in turn affects the statistical power 
and produces high rates of false positive results [80-81]. This study is unique, as its 
sample size is substantial, allowing for sufficient power in testing of ethnic differences in 
breast cancer risk factors. Additional problems that persist with genetic-association 
studies are replication and validation [82]. These inconsistencies with replication of 
genetic-association results could be due to the false positive findings, false negative 
studies, or unevenness in association among different populations [83]. Replication of 
this study among similar populations with ample sample sizes would be of importance to 
assess the validity of our findings, however this may be difficult. 
The robustness of the available covariates and other polymorphisms also allowed 
for testing of effect modification and for adjusting of common confounders; although 
sample size was more limited for testing effect modification with BMI, diabetes, and 
recent exposure to hormonal therapy. The case-control study design is susceptible to 
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common limitations, such as recall and selection bias. One variable of interest for this 
dissertation was history of diabetes. This variable was based on self-report and not 
medical record review. Exposure information from medical records would not be subject 
to recall bias [84] . For this reason, misclassification is possible when testing the 
interaction effects of diabetes with the ADRB2 haplotype. 
Although both ADRB2 genotypes and haplotypes were assessed in an effort to 
contribute to identifying other genetic risk factors within the etiology of breast cancer, 
knowledge is limited in terms of the functionality of the ADRB2 gene and its haplotypes 
in relation to the biological mechanisms associated with breast cancer risk. It could be 
argued that a better approach with this type of genetic-association study would be to 
genotype haplotype tagging SNPs, which could give a more descriptive and thorough 
assessment of the potential association between a gene and disease; however, there are 
limitations found with this approach. The reliability of the tagging SNPs with identifying 
a haplotype through resources such as HapMap, is not consistent among the genes. This 
issue is mainly caused by the selection of the tagging SNPs which is based on limited or 
fragmented linkage disequilibrium data [82]. Also, this type of genotyping may be an 
expensive endeavor in terms of genotyping costs and outside of the realm of this 
dissertation, depending upon the number of tagging SNPs identified. 
A number of multiple comparisons were made for the statistical analyses but were 
warranted due to the background knowledge of the ADRB2 gene's relationship with 
diabetes, obesity, and presumed risk of breast cancer; and statistical analyses are 
consistent in the approach and methodology with previous studies of breast cancer risk in 
the 4-CBCS [27, 31, 33, 78]. The most straightforward method for correcting p-values to 
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minimize false positives from multiple hypothesis testing is by using the Bonferroni 
correction; however, in certain cases, this method fails to consider the correlation 
between genetic variants and related phenotypes [85]. Permutation testing does give an 
empirical method to correcting p-values from multiple testing so that the correlation in 
the actual data is retained [85]. Both of these methods for minimizing false positives from 
mUltiple comparisons could be explored using SAS [86] . 
Other limitations presented with the 4-CBCS include low study response rates 
among Hispanic cases and controls, which could create a non-differential bias. In an 
effort to address these low response rates, a report for the 4-CBCS study described 
associations of age, ethnicity, and community characteristics with study nonparticipation 
for Hispanic and non-Hispanic white women [43]. It was concluded that older age was 
associated with a successful contact among Hispanic controls, but was negatively 
associated with interview cooperation. Using US Census data, it was also found that 
income, education, and urban/rural residence did not significantly affect participation by 
Hispanic cases or controls [43]. Also 25 % of the participants in the study did not 
provide a blood specimen; however, the rates of those who did give blood were similar 
among the two ethnic groups- 76.6% of cases and 82.4% of controls [41]. 
Unfortunately with all genetic studies, there is the possibility for genotyping error. 
Stochastic errors may occur and can be defined by two terms-allelic dropout and false 
alleles. Allelic dropout occurs when an allele of the heterozygote erratically fails to PCR 
amplify. False alleles occur when the true allele is misgenotyped due to 
PCR/electrophoresis artifacts or just by human error in reading or the recording of data 
[87]. Genotyping errors can introduce bias and result in false-positive findings [85]. In an 
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effort to prevent such bias, both of these situations were addressed, as drop outs were re-
analyzed and all genotypes were "called" or scored by two individuals with any 
discrepancies being scored by a third reader. 
This dissertation is just one of few studies that examined the potential association 
between the ADRB2 gene and breast cancer risk. Given the associations with both Type 
2 diabetes and obesity, it is likely that both somehow playa role with the ADRB2 
relationship and risk of breast cancer. It is important for future population-based studies 
to investigate this relationship among other ethnic groups, due to the previously discussed 
characteristics of this specific gene's polymorphisms and haplotypes. Ideally, multicenter 
collaborations with much larger sample sizes would be the next step to improving 
genetic-association studies such as this study; however the cost of such studies would be 
highly expensive. These investigations would be of importance as they could account for 
biological disparities in breast cancer incidence. There are also other implications for 
future biological research to gain more knowledge about the biological mechanism that 
contributes to this possible association with breast cancer and possible ethnic differences. 
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